[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fsgry-lU3knc3CE6F6yeIyg-gLNV1wi7bOir3f3A8FwY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":84,"rows":91},"Boston Children's Hospital",[4],597,false,173,24,227681,56,455,[14,17,20,22,25,28,31,34],{"name":15,"count":16},"Congenital Heart Disease",25,{"name":18,"count":19},"Asthma",16,{"name":21,"count":19},"Obesity",{"name":23,"count":24},"Cystic Fibrosis",14,{"name":26,"count":27},"Autism Spectrum Disorder",13,{"name":29,"count":30},"Alcohol Abuse",10,{"name":32,"count":33},"Epilepsy",9,{"name":35,"count":33},"Anesthesia",[37,42,47,52,57,61,66,71,76,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03386539","Tacrolimus\u002FEverolimus vs. Tacrolimus\u002FMMF in Pediatric Heart Transplant Recipients Using the MATE Score","2023-04-17","Everolimus",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03655665","Does Topical Otic Drop Use at Time of Tympanostomy Tube Surgery Improve Outcomes When no Middle Ear Effusion is Present","2024-09","Ofloxacin otic solution",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03532399","Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation","2026-05","Bivalirudin",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06779825","Impact of Stimulants and In-Scanner Motion on Attentive Task Performance in ADHD (ADHD_NFB)","2026-06","fMRI Neurofeedback attention task",{"nctId":58,"briefTitle":59,"date":55,"intervention":60},"NCT05378555","Oral Ketamine for Treatment of Vaso-Occlusive Pain","Ketamine Hydrochloride",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07513038","Use of Indocyanine Green (ICG) for the Diagnosis of Biliary Atresia","2026-08","Indocyanine Green",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT03593408","Pharmacokinetics of Sedatives and Analgesics During Extracorporeal Membrane Oxygenation (ECMO) Support","2026-08-01","Dexmedetomidine",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT03054831","The Effect of General Anesthesia on Pharmacokinetics of Oxycodone in Pediatric","2026-12","liquid oxycodone",{"nctId":77,"briefTitle":78,"date":74,"intervention":79},"NCT03102554","Genetics of Differences of Sex Development and Hypospadias","Return of Genetic Results",{"nctId":81,"briefTitle":82,"date":74,"intervention":83},"NCT01659606","Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita","alemtuzumab",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,145,171,213,235,269,287,305,323,341,359,377,399,417,443,470,488,513,538,596,630,663,685,707,736,760,778,810,828,846,864,882,929,987,1012,1039,1065,1089,1107,1125,1146,1183,1211,1235,1313,1335,1353,1379,1399,1421,1445,1464,1492,1510,1536,1554,1572,1606,1630,1657,1675,1699,1724,1752,1770,1795,1819,1844,1862,1888,1914,1939,1957,1983,2001,2043,2067,2096,2114,2141,2167,2185,2210,2235,2253,2278,2296,2314,2332,2356,2388,2424,2446,2480,2498,2522,2547,2572,2596,2620,2643,2661,2686,2704,2728,2753,2777,2801,2819,2843,2868,2886,2912,2937,2963,2986,3004,3026,3047,3072,3090,3114,3132,3150,3174,3198,3221,3245,3268,3291,3309,3331,3355,3380,3402,3425,3448,3471,3521,3552,3579,3615,3637,3662,3680,3701,3725,3747,3773,3791,3813,3831,3855,3873,3896,3921,3939,3965,3983,4006,4036,4061,4079,4105,4131,4155,4178,4202,4220,4243],{"intervention":93,"totalTrials":94,"cells":95},"low bile acid binding blenderized diet",3,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":134},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":98},[],{"trials":104,"activeCount":98},[],{"trials":106,"activeCount":133,"soonestReadout":112},[107,122],{"nctId":108,"briefTitle":109,"status":110,"phases":111,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":119},"NCT07303868","The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 2)","NOT_YET_RECRUITING",[89],"2030-08","2026-07",66,[116,117,118],"Feeding Difficulties","Gastrostomy","Aspiration",[120,121],"Low bile acid binding blenderized diet","High bile acid binding blenderized diet",{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":112,"completion":112,"start":127,"enrollment":128,"conditions":129,"interventions":130},"NCT07303738","The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 1)","RECRUITING",[89],"2025-12-01",60,[116,118,117],[131,93,132],"amino acid based formula","high bile acid binding blenderized diet",2,{"trials":135,"activeCount":144,"soonestReadout":112},[136],{"nctId":137,"briefTitle":138,"status":110,"phases":139,"primaryCompletion":112,"completion":112,"start":113,"enrollment":140,"conditions":141,"interventions":142},"NCT06913621","The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 3)",[],138,[116,117,118],[143,93,132],"amino acid formula",1,{"intervention":132,"totalTrials":94,"cells":146},{"EARLY_PHASE1":147,"PHASE1":149,"PHASE2":151,"PHASE3":153,"PHASE4":155,"NA":165},{"trials":148,"activeCount":98},[],{"trials":150,"activeCount":98},[],{"trials":152,"activeCount":98},[],{"trials":154,"activeCount":98},[],{"trials":156,"activeCount":133,"soonestReadout":112},[157,161],{"nctId":108,"briefTitle":109,"status":110,"phases":158,"primaryCompletion":112,"completion":112,"start":113,"enrollment":114,"conditions":159,"interventions":160},[89],[116,117,118],[120,121],{"nctId":123,"briefTitle":124,"status":125,"phases":162,"primaryCompletion":112,"completion":112,"start":127,"enrollment":128,"conditions":163,"interventions":164},[89],[116,118,117],[131,93,132],{"trials":166,"activeCount":144,"soonestReadout":112},[167],{"nctId":137,"briefTitle":138,"status":110,"phases":168,"primaryCompletion":112,"completion":112,"start":113,"enrollment":140,"conditions":169,"interventions":170},[],[116,117,118],[143,93,132],{"intervention":172,"totalTrials":133,"cells":173},"Famotidine",{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":182,"NA":211},{"trials":175,"activeCount":98},[],{"trials":177,"activeCount":98},[],{"trials":179,"activeCount":98},[],{"trials":181,"activeCount":98},[],{"trials":183,"activeCount":144,"soonestReadout":188},[184,198],{"nctId":185,"briefTitle":186,"status":125,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":196},"NCT05455359","Gastrointestinal Dysmotility on Aspiration Risk",[89],"2027-05-31","2025-02-13",120,[192,193,194,195],"Esophageal Motility Disorders","Gastric Motor Dysfunction","Aspiration Pneumonia","Gastro Esophageal Reflux",[197,172],"Prucalopride",{"nctId":199,"briefTitle":200,"status":201,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":210},"NCT03667703","Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease","COMPLETED",[89],"2022-06-30","2019-03-10",70,[15,207,208,209],"Upper Gastrointestinal Bleeding","Stress Ulcer","Infection",[172],{"trials":212,"activeCount":98},[],{"intervention":46,"totalTrials":144,"cells":214},{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":223,"NA":233},{"trials":216,"activeCount":98},[],{"trials":218,"activeCount":98},[],{"trials":220,"activeCount":98},[],{"trials":222,"activeCount":98},[],{"trials":224,"activeCount":144,"soonestReadout":45},[225],{"nctId":43,"briefTitle":44,"status":125,"phases":226,"primaryCompletion":45,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},[89],"2026-09","2019-05-16",125,[231],"Otitis Media",[46],{"trials":234,"activeCount":98},[],{"intervention":236,"totalTrials":144,"cells":237},"Dexmedetomidine (IV) 0.5 mcg\u002Fkg",{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":267},{"trials":239,"activeCount":98},[],{"trials":241,"activeCount":98},[],{"trials":243,"activeCount":98},[],{"trials":245,"activeCount":98},[],{"trials":247,"activeCount":144,"soonestReadout":252},[248],{"nctId":249,"briefTitle":250,"status":125,"phases":251,"primaryCompletion":252,"completion":253,"start":55,"enrollment":254,"conditions":255,"interventions":261},"NCT07369128","Propofol-Only Versus Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging",[89],"2027-12","2028-03",105,[256,257,258,259,260,70],"MRI Sedation","Pediatric Sedation","Propofol Dosage","Emergence Delirium, Anesthesia","Recovery Time",[236,262,263,264,265,266],"Propofol (IV) 2-4 mg\u002Fkg","Dexmedetomidine (IV) 1 mcg\u002Fkg","Propofol (IV) 1-2 mg\u002Fkg","Propofol (IV) Infusion 250 mcg\u002Fkg\u002Fmin","Propofol (IV) Infusion 150 mcg\u002Fkg\u002Fmin",{"trials":268,"activeCount":98},[],{"intervention":262,"totalTrials":144,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":285},{"trials":272,"activeCount":98},[],{"trials":274,"activeCount":98},[],{"trials":276,"activeCount":98},[],{"trials":278,"activeCount":98},[],{"trials":280,"activeCount":144,"soonestReadout":252},[281],{"nctId":249,"briefTitle":250,"status":125,"phases":282,"primaryCompletion":252,"completion":253,"start":55,"enrollment":254,"conditions":283,"interventions":284},[89],[256,257,258,259,260,70],[236,262,263,264,265,266],{"trials":286,"activeCount":98},[],{"intervention":263,"totalTrials":144,"cells":288},{"EARLY_PHASE1":289,"PHASE1":291,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":303},{"trials":290,"activeCount":98},[],{"trials":292,"activeCount":98},[],{"trials":294,"activeCount":98},[],{"trials":296,"activeCount":98},[],{"trials":298,"activeCount":144,"soonestReadout":252},[299],{"nctId":249,"briefTitle":250,"status":125,"phases":300,"primaryCompletion":252,"completion":253,"start":55,"enrollment":254,"conditions":301,"interventions":302},[89],[256,257,258,259,260,70],[236,262,263,264,265,266],{"trials":304,"activeCount":98},[],{"intervention":264,"totalTrials":144,"cells":306},{"EARLY_PHASE1":307,"PHASE1":309,"PHASE2":311,"PHASE3":313,"PHASE4":315,"NA":321},{"trials":308,"activeCount":98},[],{"trials":310,"activeCount":98},[],{"trials":312,"activeCount":98},[],{"trials":314,"activeCount":98},[],{"trials":316,"activeCount":144,"soonestReadout":252},[317],{"nctId":249,"briefTitle":250,"status":125,"phases":318,"primaryCompletion":252,"completion":253,"start":55,"enrollment":254,"conditions":319,"interventions":320},[89],[256,257,258,259,260,70],[236,262,263,264,265,266],{"trials":322,"activeCount":98},[],{"intervention":265,"totalTrials":144,"cells":324},{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":339},{"trials":326,"activeCount":98},[],{"trials":328,"activeCount":98},[],{"trials":330,"activeCount":98},[],{"trials":332,"activeCount":98},[],{"trials":334,"activeCount":144,"soonestReadout":252},[335],{"nctId":249,"briefTitle":250,"status":125,"phases":336,"primaryCompletion":252,"completion":253,"start":55,"enrollment":254,"conditions":337,"interventions":338},[89],[256,257,258,259,260,70],[236,262,263,264,265,266],{"trials":340,"activeCount":98},[],{"intervention":266,"totalTrials":144,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":349,"PHASE4":351,"NA":357},{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":98},[],{"trials":348,"activeCount":98},[],{"trials":350,"activeCount":98},[],{"trials":352,"activeCount":144,"soonestReadout":252},[353],{"nctId":249,"briefTitle":250,"status":125,"phases":354,"primaryCompletion":252,"completion":253,"start":55,"enrollment":254,"conditions":355,"interventions":356},[89],[256,257,258,259,260,70],[236,262,263,264,265,266],{"trials":358,"activeCount":98},[],{"intervention":197,"totalTrials":144,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":369,"NA":375},{"trials":362,"activeCount":98},[],{"trials":364,"activeCount":98},[],{"trials":366,"activeCount":98},[],{"trials":368,"activeCount":98},[],{"trials":370,"activeCount":144,"soonestReadout":188},[371],{"nctId":185,"briefTitle":186,"status":125,"phases":372,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":373,"interventions":374},[89],[192,193,194,195],[197,172],{"trials":376,"activeCount":98},[],{"intervention":75,"totalTrials":144,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":397},{"trials":380,"activeCount":98},[],{"trials":382,"activeCount":98},[],{"trials":384,"activeCount":98},[],{"trials":386,"activeCount":98},[],{"trials":388,"activeCount":144,"soonestReadout":74},[389],{"nctId":72,"briefTitle":73,"status":390,"phases":391,"primaryCompletion":74,"completion":252,"start":392,"enrollment":393,"conditions":394,"interventions":396},"ACTIVE_NOT_RECRUITING",[89],"2019-07-08",40,[395],"Liquid Oxycodone",[75],{"trials":398,"activeCount":98},[],{"intervention":131,"totalTrials":144,"cells":400},{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":415},{"trials":402,"activeCount":98},[],{"trials":404,"activeCount":98},[],{"trials":406,"activeCount":98},[],{"trials":408,"activeCount":98},[],{"trials":410,"activeCount":144,"soonestReadout":112},[411],{"nctId":123,"briefTitle":124,"status":125,"phases":412,"primaryCompletion":112,"completion":112,"start":127,"enrollment":128,"conditions":413,"interventions":414},[89],[116,118,117],[131,93,132],{"trials":416,"activeCount":98},[],{"intervention":418,"totalTrials":144,"cells":419},"Skin Cleanser Combination No.1",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":441},{"trials":421,"activeCount":98},[],{"trials":423,"activeCount":98},[],{"trials":425,"activeCount":98},[],{"trials":427,"activeCount":98},[],{"trials":429,"activeCount":144,"soonestReadout":434},[430],{"nctId":431,"briefTitle":432,"status":110,"phases":433,"primaryCompletion":434,"completion":435,"start":436,"enrollment":437,"conditions":438,"interventions":440},"NCT06397781","Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients",[89],"2035-12","2039-12","2031-01-01",100,[439],"Atopic Dermatitis",[418],{"trials":442,"activeCount":98},[],{"intervention":444,"totalTrials":144,"cells":445},"methylprednisolone acetate and lidocaine",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":468},{"trials":447,"activeCount":98},[],{"trials":449,"activeCount":98},[],{"trials":451,"activeCount":98},[],{"trials":453,"activeCount":98},[],{"trials":455,"activeCount":144,"soonestReadout":460},[456],{"nctId":457,"briefTitle":458,"status":125,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":466},"NCT07255248","Hoffa's Fat Pad Impingement (HFPI)",[89],"2027-11-01","2028-01-02","2026-03-01",62,[465],"Hoffa's Fat Pad Impingement",[444,467],"Saline",{"trials":469,"activeCount":98},[],{"intervention":467,"totalTrials":144,"cells":471},{"EARLY_PHASE1":472,"PHASE1":474,"PHASE2":476,"PHASE3":478,"PHASE4":480,"NA":486},{"trials":473,"activeCount":98},[],{"trials":475,"activeCount":98},[],{"trials":477,"activeCount":98},[],{"trials":479,"activeCount":98},[],{"trials":481,"activeCount":144,"soonestReadout":460},[482],{"nctId":457,"briefTitle":458,"status":125,"phases":483,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":484,"interventions":485},[89],[465],[444,467],{"trials":487,"activeCount":98},[],{"intervention":489,"totalTrials":144,"cells":490},"oral oxycodone",{"EARLY_PHASE1":491,"PHASE1":493,"PHASE2":495,"PHASE3":497,"PHASE4":499,"NA":511},{"trials":492,"activeCount":98},[],{"trials":494,"activeCount":98},[],{"trials":496,"activeCount":98},[],{"trials":498,"activeCount":98},[],{"trials":500,"activeCount":144,"soonestReadout":505},[501],{"nctId":502,"briefTitle":503,"status":390,"phases":504,"primaryCompletion":505,"completion":252,"start":506,"enrollment":507,"conditions":508,"interventions":510},"NCT02044497","Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients",[89],"2027-05","2014-05",68,[509],"Pediatric Surgical Patient",[489],{"trials":512,"activeCount":98},[],{"intervention":514,"totalTrials":144,"cells":515},"Dupilumab",{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":524,"NA":536},{"trials":517,"activeCount":98},[],{"trials":519,"activeCount":98},[],{"trials":521,"activeCount":98},[],{"trials":523,"activeCount":98},[],{"trials":525,"activeCount":144,"soonestReadout":530},[526],{"nctId":527,"briefTitle":528,"status":390,"phases":529,"primaryCompletion":530,"completion":531,"start":532,"enrollment":533,"conditions":534,"interventions":535},"NCT03694158","Investigating Dupilumab's Effect in Asthma by Genotype",[89],"2027-01","2027-03","2021-09-08",150,[18],[514],{"trials":537,"activeCount":98},[],{"intervention":539,"totalTrials":94,"cells":540},"Tacrolimus",{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":560,"PHASE4":592,"NA":594},{"trials":542,"activeCount":98},[],{"trials":544,"activeCount":98},[],{"trials":546,"activeCount":144,"soonestReadout":74},[547],{"nctId":81,"briefTitle":82,"status":390,"phases":548,"primaryCompletion":74,"completion":549,"start":550,"enrollment":393,"conditions":551,"interventions":556},[87],"2034-12","2012-07",[552,553,554,555],"Dyskeratosis Congenita","Hoyeraal Hreidarsson Syndrome","Revesz Syndrome","Aplastic Anemia",[83,557,558,559,539],"Fludarabine","Cyclosporins","Mycophenolate mofetil",{"trials":561,"activeCount":144,"soonestReadout":40},[562,577],{"nctId":563,"briefTitle":564,"status":565,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":571,"interventions":574},"NCT00005113","A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant","TERMINATED",[88],"2004-07","2006-03","1999-07",102,[572,573],"End-Stage Renal Disease","Kidney Transplantation",[575,576,539],"Cyclosporine","Sirolimus",{"nctId":38,"briefTitle":39,"status":390,"phases":578,"primaryCompletion":40,"completion":579,"start":580,"enrollment":581,"conditions":582,"interventions":590},[88],"2024-01","2018-01-29",211,[583,584,585,586,587,588,589],"Pediatric Heart Transplantation","Immunosuppression","Chronic Kidney Diseases","Cardiac Allograft Vasculopathy","Heart Transplant Failure and Rejection","Post-transplant Lymphoproliferative Disorder","Heart Transplant Infection",[41,539,591],"Mycophenolate Mofetil",{"trials":593,"activeCount":98},[],{"trials":595,"activeCount":98},[],{"intervention":597,"totalTrials":133,"cells":598},"Ketamine hydrochloride",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":603,"PHASE3":605,"PHASE4":626,"NA":628},{"trials":600,"activeCount":98},[],{"trials":602,"activeCount":98},[],{"trials":604,"activeCount":98},[],{"trials":606,"activeCount":133,"soonestReadout":55},[607,619],{"nctId":608,"briefTitle":609,"status":110,"phases":610,"primaryCompletion":611,"completion":612,"start":613,"enrollment":614,"conditions":615,"interventions":618},"NCT07450430","Optimal Timing of Ketamine Initiation for SCD Pain",[88],"2029-02","2030-02","2026-02",90,[616,617],"Sickle Cell Disease","Sickle Cell Crisis",[597],{"nctId":58,"briefTitle":59,"status":125,"phases":620,"primaryCompletion":55,"completion":621,"start":622,"enrollment":30,"conditions":623,"interventions":625},[88],"2026-06-01","2023-05-01",[624],"Vaso-occlusive Crisis",[60],{"trials":627,"activeCount":98},[],{"trials":629,"activeCount":98},[],{"intervention":557,"totalTrials":133,"cells":631},{"EARLY_PHASE1":632,"PHASE1":634,"PHASE2":636,"PHASE3":642,"PHASE4":659,"NA":661},{"trials":633,"activeCount":98},[],{"trials":635,"activeCount":98},[],{"trials":637,"activeCount":144,"soonestReadout":74},[638],{"nctId":81,"briefTitle":82,"status":390,"phases":639,"primaryCompletion":74,"completion":549,"start":550,"enrollment":393,"conditions":640,"interventions":641},[87],[552,553,554,555],[83,557,558,559,539],{"trials":643,"activeCount":144,"soonestReadout":648},[644],{"nctId":645,"briefTitle":646,"status":390,"phases":647,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":653},"NCT05600426","A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)",[88],"2029-12","2023-01-25",53,[652],"Severe Aplastic Anemia",[654,655,656,657,557,658],"cyclosporine","horse anti-thymocyte globulin","rabbit anti-thymocyte globulin","Methotrexate","Cyclophosphamide",{"trials":660,"activeCount":98},[],{"trials":662,"activeCount":98},[],{"intervention":591,"totalTrials":133,"cells":664},{"EARLY_PHASE1":665,"PHASE1":667,"PHASE2":669,"PHASE3":675,"PHASE4":681,"NA":683},{"trials":666,"activeCount":98},[],{"trials":668,"activeCount":98},[],{"trials":670,"activeCount":144,"soonestReadout":74},[671],{"nctId":81,"briefTitle":82,"status":390,"phases":672,"primaryCompletion":74,"completion":549,"start":550,"enrollment":393,"conditions":673,"interventions":674},[87],[552,553,554,555],[83,557,558,559,539],{"trials":676,"activeCount":144,"soonestReadout":40},[677],{"nctId":38,"briefTitle":39,"status":390,"phases":678,"primaryCompletion":40,"completion":579,"start":580,"enrollment":581,"conditions":679,"interventions":680},[88],[583,584,585,586,587,588,589],[41,539,591],{"trials":682,"activeCount":98},[],{"trials":684,"activeCount":98},[],{"intervention":575,"totalTrials":133,"cells":686},{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":691,"PHASE3":693,"PHASE4":703,"NA":705},{"trials":688,"activeCount":98},[],{"trials":690,"activeCount":98},[],{"trials":692,"activeCount":98},[],{"trials":694,"activeCount":144,"soonestReadout":648},[695,699],{"nctId":563,"briefTitle":564,"status":565,"phases":696,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":697,"interventions":698},[88],[572,573],[575,576,539],{"nctId":645,"briefTitle":646,"status":390,"phases":700,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":701,"interventions":702},[88],[652],[654,655,656,657,557,658],{"trials":704,"activeCount":98},[],{"trials":706,"activeCount":98},[],{"intervention":657,"totalTrials":133,"cells":708},{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":726,"PHASE4":732,"NA":734},{"trials":710,"activeCount":98},[],{"trials":712,"activeCount":98},[],{"trials":714,"activeCount":98},[715],{"nctId":716,"briefTitle":717,"status":201,"phases":718,"primaryCompletion":719,"completion":719,"start":720,"enrollment":721,"conditions":722,"interventions":724},"NCT00215046","Vinblastine and Methotrexate in Children With Pulmonary Vein Stenosis",[87],"2006-10","2000-03",28,[723],"Intraluminal Pulmonary Vein Stenosis",[725,657],"Vinblastine",{"trials":727,"activeCount":144,"soonestReadout":648},[728],{"nctId":645,"briefTitle":646,"status":390,"phases":729,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":730,"interventions":731},[88],[652],[654,655,656,657,557,658],{"trials":733,"activeCount":98},[],{"trials":735,"activeCount":98},[],{"intervention":737,"totalTrials":144,"cells":738},"Gabapentin",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":745,"PHASE4":756,"NA":758},{"trials":740,"activeCount":98},[],{"trials":742,"activeCount":98},[],{"trials":744,"activeCount":98},[],{"trials":746,"activeCount":144,"soonestReadout":751},[747],{"nctId":748,"briefTitle":749,"status":110,"phases":750,"primaryCompletion":751,"completion":751,"start":55,"enrollment":128,"conditions":752,"interventions":754},"NCT02219373","Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study",[88],"2028-12",[753],"Pediatric Chronic Neuropathic Pain",[737,755],"Oxcarbazepine",{"trials":757,"activeCount":98},[],{"trials":759,"activeCount":98},[],{"intervention":755,"totalTrials":144,"cells":761},{"EARLY_PHASE1":762,"PHASE1":764,"PHASE2":766,"PHASE3":768,"PHASE4":774,"NA":776},{"trials":763,"activeCount":98},[],{"trials":765,"activeCount":98},[],{"trials":767,"activeCount":98},[],{"trials":769,"activeCount":144,"soonestReadout":751},[770],{"nctId":748,"briefTitle":749,"status":110,"phases":771,"primaryCompletion":751,"completion":751,"start":55,"enrollment":128,"conditions":772,"interventions":773},[88],[753],[737,755],{"trials":775,"activeCount":98},[],{"trials":777,"activeCount":98},[],{"intervention":779,"totalTrials":144,"cells":780},"Everolimus blinded oral",{"EARLY_PHASE1":781,"PHASE1":783,"PHASE2":785,"PHASE3":787,"PHASE4":806,"NA":808},{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":98},[],{"trials":788,"activeCount":144,"soonestReadout":793},[789],{"nctId":790,"briefTitle":791,"status":110,"phases":792,"primaryCompletion":793,"completion":793,"start":794,"enrollment":128,"conditions":795,"interventions":805},"NCT07218575","Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations",[87,88],"2030-04","2026-04",[796,797,798,799,800,801,802,803,804],"Cowden's Disease","Cowden's Syndrome","Lhermitte-Duclos Disease","Cerebellum Dysplastic Gangliocytoma","Bannayan Zonana Syndrome","Myhre Riley Smith Syndrome","Riley Smith Syndrome","PTEN Hamartoma Tumor Syndrome","Bannayan Riley Ruvalcaba Syndrome",[779],{"trials":807,"activeCount":98},[],{"trials":809,"activeCount":98},[],{"intervention":655,"totalTrials":144,"cells":811},{"EARLY_PHASE1":812,"PHASE1":814,"PHASE2":816,"PHASE3":818,"PHASE4":824,"NA":826},{"trials":813,"activeCount":98},[],{"trials":815,"activeCount":98},[],{"trials":817,"activeCount":98},[],{"trials":819,"activeCount":144,"soonestReadout":648},[820],{"nctId":645,"briefTitle":646,"status":390,"phases":821,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":822,"interventions":823},[88],[652],[654,655,656,657,557,658],{"trials":825,"activeCount":98},[],{"trials":827,"activeCount":98},[],{"intervention":656,"totalTrials":144,"cells":829},{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":842,"NA":844},{"trials":831,"activeCount":98},[],{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":98},[],{"trials":837,"activeCount":144,"soonestReadout":648},[838],{"nctId":645,"briefTitle":646,"status":390,"phases":839,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":840,"interventions":841},[88],[652],[654,655,656,657,557,658],{"trials":843,"activeCount":98},[],{"trials":845,"activeCount":98},[],{"intervention":658,"totalTrials":144,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":860,"NA":862},{"trials":849,"activeCount":98},[],{"trials":851,"activeCount":98},[],{"trials":853,"activeCount":98},[],{"trials":855,"activeCount":144,"soonestReadout":648},[856],{"nctId":645,"briefTitle":646,"status":390,"phases":857,"primaryCompletion":648,"completion":648,"start":649,"enrollment":650,"conditions":858,"interventions":859},[88],[652],[654,655,656,657,557,658],{"trials":861,"activeCount":98},[],{"trials":863,"activeCount":98},[],{"intervention":41,"totalTrials":144,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":878,"NA":880},{"trials":867,"activeCount":98},[],{"trials":869,"activeCount":98},[],{"trials":871,"activeCount":98},[],{"trials":873,"activeCount":144,"soonestReadout":40},[874],{"nctId":38,"briefTitle":39,"status":390,"phases":875,"primaryCompletion":40,"completion":579,"start":580,"enrollment":581,"conditions":876,"interventions":877},[88],[583,584,585,586,587,588,589],[41,539,591],{"trials":879,"activeCount":98},[],{"trials":881,"activeCount":98},[],{"intervention":883,"totalTrials":94,"cells":884},"Omalizumab",{"EARLY_PHASE1":885,"PHASE1":897,"PHASE2":899,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":886,"activeCount":98},[887],{"nctId":888,"briefTitle":889,"status":201,"phases":890,"primaryCompletion":891,"completion":891,"start":892,"enrollment":30,"conditions":893,"interventions":895},"NCT00968110","Xolair Treatment for Milk Allergic Children",[85],"2017-04","2009-03",[894],"Milk Allergy",[896],"omalizumab",{"trials":898,"activeCount":98},[],{"trials":900,"activeCount":144,"soonestReadout":917},[901,913],{"nctId":902,"briefTitle":903,"status":201,"phases":904,"primaryCompletion":905,"completion":906,"start":907,"enrollment":908,"conditions":909,"interventions":912},"NCT01781637","Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial",[86,87],"2015-10","2022-05-31","2013-01",36,[910,911],"Peanut Allergy","Food Allergy",[883],{"nctId":914,"briefTitle":915,"status":390,"phases":916,"primaryCompletion":917,"completion":918,"start":919,"enrollment":920,"conditions":921,"interventions":922},"NCT02570984","Preventing Asthma in High Risk Kids",[87],"2028-01-31","2028-03-31","2018-11-27",200,[18],[883],{"trials":924,"activeCount":98},[],{"trials":926,"activeCount":98},[],{"trials":928,"activeCount":98},[],{"intervention":930,"totalTrials":94,"cells":931},"Abatacept",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":933,"activeCount":98},[],{"trials":935,"activeCount":98},[],{"trials":937,"activeCount":144,"soonestReadout":505},[938,959,971],{"nctId":939,"briefTitle":940,"status":201,"phases":941,"primaryCompletion":942,"completion":907,"start":943,"enrollment":944,"conditions":945,"interventions":958},"NCT01012492","Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT",[87],"2012-11","2009-11",11,[946,947,948,949,950,951,952,953,954,955,956,957],"AML","ALL","Undifferentiated Leukemia","Biphenotypic Leukemia","Refractory Anemia","Refractory Anemia With Ringed Sideroblasts","Refractory Cytopenia With Multilineage Dysplasia","Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts","Refractory Anemia With Excess Blasts-1 (5-10% Blasts)","Refractory Anemia With Excess Blasts-2 (10-20% Blasts)","Myelodysplastic Syndrome, Unclassified","MDS Associated With Isolated Del (5q)",[930],{"nctId":960,"briefTitle":961,"status":201,"phases":962,"primaryCompletion":963,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":970},"NCT01743131","Abatacept as GVHD Prophylaxis Phase 2",[87],"2018-06-30","2024-03-30","2013-02-01",186,[968,969],"Graft vs Host Disease","Malignancy",[930],{"nctId":972,"briefTitle":973,"status":125,"phases":974,"primaryCompletion":505,"completion":975,"start":976,"enrollment":977,"conditions":978,"interventions":980},"NCT04380740","Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis",[87],"2028-06","2022-03-30",160,[979],"Graft Vs Host Disease",[930],{"trials":982,"activeCount":98},[],{"trials":984,"activeCount":98},[],{"trials":986,"activeCount":98},[],{"intervention":988,"totalTrials":144,"cells":989},"Everolimus and lonafarnib",{"EARLY_PHASE1":990,"PHASE1":992,"PHASE2":994,"PHASE3":1006,"PHASE4":1008,"NA":1010},{"trials":991,"activeCount":98},[],{"trials":993,"activeCount":98},[],{"trials":995,"activeCount":144,"soonestReadout":531},[996],{"nctId":997,"briefTitle":998,"status":999,"phases":1000,"primaryCompletion":531,"completion":531,"start":1001,"enrollment":1002,"conditions":1003,"interventions":1005},"NCT02579044","Phase I\u002FII Trial of Everolimus in Combination With Lonafarnib in Progeria","ENROLLING_BY_INVITATION",[86,87],"2015-12",80,[1004],"Progeria",[988],{"trials":1007,"activeCount":98},[],{"trials":1009,"activeCount":98},[],{"trials":1011,"activeCount":98},[],{"intervention":1013,"totalTrials":144,"cells":1014},"Valproate",{"EARLY_PHASE1":1015,"PHASE1":1017,"PHASE2":1019,"PHASE3":1033,"PHASE4":1035,"NA":1037},{"trials":1016,"activeCount":98},[],{"trials":1018,"activeCount":98},[],{"trials":1020,"activeCount":144,"soonestReadout":1025},[1021],{"nctId":1022,"briefTitle":1023,"status":110,"phases":1024,"primaryCompletion":1025,"completion":1025,"start":1026,"enrollment":721,"conditions":1027,"interventions":1032},"NCT07226141","Valproate for the Treatment of Residual Amblyopia",[86,87],"2027-09-30","2026-01-01",[1028,1029,1030,1031],"Amblyopia","Amblyopia Unilateral","Amblyopia, Anisometropic","Amblyopia Strabismic",[1013],{"trials":1034,"activeCount":98},[],{"trials":1036,"activeCount":98},[],{"trials":1038,"activeCount":98},[],{"intervention":1040,"totalTrials":144,"cells":1041},"Interleukin-2 (aldesleukin).",{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1059,"PHASE4":1061,"NA":1063},{"trials":1043,"activeCount":98},[],{"trials":1045,"activeCount":98},[],{"trials":1047,"activeCount":144,"soonestReadout":1052},[1048],{"nctId":1049,"briefTitle":1050,"status":125,"phases":1051,"primaryCompletion":1052,"completion":1053,"start":1054,"enrollment":1055,"conditions":1056,"interventions":1058},"NCT04263831","Low Dose IL-2 for the Treatment of Crohn's Disease",[86,87],"2026-12-31","2027-12-31","2021-03-11",30,[1057],"Crohn Disease",[1040],{"trials":1060,"activeCount":98},[],{"trials":1062,"activeCount":98},[],{"trials":1064,"activeCount":98},[],{"intervention":1066,"totalTrials":144,"cells":1067},"Metformin Hydrochloride",{"EARLY_PHASE1":1068,"PHASE1":1070,"PHASE2":1072,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1069,"activeCount":98},[],{"trials":1071,"activeCount":98},[],{"trials":1073,"activeCount":144,"soonestReadout":530},[1074],{"nctId":1075,"briefTitle":1076,"status":125,"phases":1077,"primaryCompletion":530,"completion":530,"start":1078,"enrollment":24,"conditions":1079,"interventions":1082},"NCT06611501","Glycemic Regulation as Endometriosis Adjunct Treatment",[87],"2025-05-22",[1080,1081],"Pelvic Pain","Endometriosis",[1066],{"trials":1084,"activeCount":98},[],{"trials":1086,"activeCount":98},[],{"trials":1088,"activeCount":98},[],{"intervention":83,"totalTrials":144,"cells":1090},{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1101,"PHASE4":1103,"NA":1105},{"trials":1092,"activeCount":98},[],{"trials":1094,"activeCount":98},[],{"trials":1096,"activeCount":144,"soonestReadout":74},[1097],{"nctId":81,"briefTitle":82,"status":390,"phases":1098,"primaryCompletion":74,"completion":549,"start":550,"enrollment":393,"conditions":1099,"interventions":1100},[87],[552,553,554,555],[83,557,558,559,539],{"trials":1102,"activeCount":98},[],{"trials":1104,"activeCount":98},[],{"trials":1106,"activeCount":98},[],{"intervention":558,"totalTrials":144,"cells":1108},{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1110,"activeCount":98},[],{"trials":1112,"activeCount":98},[],{"trials":1114,"activeCount":144,"soonestReadout":74},[1115],{"nctId":81,"briefTitle":82,"status":390,"phases":1116,"primaryCompletion":74,"completion":549,"start":550,"enrollment":393,"conditions":1117,"interventions":1118},[87],[552,553,554,555],[83,557,558,559,539],{"trials":1120,"activeCount":98},[],{"trials":1122,"activeCount":98},[],{"trials":1124,"activeCount":98},[],{"intervention":65,"totalTrials":144,"cells":1126},{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1131,"PHASE3":1140,"PHASE4":1142,"NA":1144},{"trials":1128,"activeCount":98},[],{"trials":1130,"activeCount":98},[],{"trials":1132,"activeCount":144,"soonestReadout":64},[1133],{"nctId":62,"briefTitle":63,"status":125,"phases":1134,"primaryCompletion":64,"completion":74,"start":1135,"enrollment":1136,"conditions":1137,"interventions":1139},[86,87],"2024-08-01",20,[1138],"Biliary Atresia",[65],{"trials":1141,"activeCount":98},[],{"trials":1143,"activeCount":98},[],{"trials":1145,"activeCount":98},[],{"intervention":1147,"totalTrials":133,"cells":1148},"Hydrogen",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1175,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1150,"activeCount":98},[],{"trials":1152,"activeCount":144,"soonestReadout":1167},[1153,1163],{"nctId":1154,"briefTitle":1155,"status":201,"phases":1156,"primaryCompletion":1157,"completion":1157,"start":1158,"enrollment":1159,"conditions":1160,"interventions":1162},"NCT04046211","Safety of Inhaled Hydrogen Gas Mixtures in Healthy Volunteers",[86],"2021-05-01","2020-10-26",8,[1161],"Healthy",[1147],{"nctId":1164,"briefTitle":1165,"status":125,"phases":1166,"primaryCompletion":1167,"completion":1168,"start":1169,"enrollment":650,"conditions":1170,"interventions":1174},"NCT05574296","Hydrogen's Feasibility and Safety as a Therapy in ECPR",[86],"2027-03-31","2027-08-31","2024-03-04",[1171,1172,1173],"Cardiac Arrest","Extracorporeal Membrane Oxygenation","Reperfusion Injury",[1147],{"trials":1176,"activeCount":98},[],{"trials":1178,"activeCount":98},[],{"trials":1180,"activeCount":98},[],{"trials":1182,"activeCount":98},[],{"intervention":1184,"totalTrials":144,"cells":1185},"Metformin",{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1203,"PHASE3":1205,"PHASE4":1207,"NA":1209},{"trials":1187,"activeCount":98},[],{"trials":1189,"activeCount":144,"soonestReadout":1194},[1190],{"nctId":1191,"briefTitle":1192,"status":999,"phases":1193,"primaryCompletion":1194,"completion":1195,"start":1196,"enrollment":1055,"conditions":1197,"interventions":1202},"NCT06429007","A Safety and Feasibility Trial Protocol of Metformin in Infants After Perinatal Brain Injury",[86],"2028-01-01","2029-03-01","2025-10-01",[1198,1199,1200,1201],"Hypoxic-Ischemic Encephalopathy","HIE","Neurodevelopment","Infant Development",[1184],{"trials":1204,"activeCount":98},[],{"trials":1206,"activeCount":98},[],{"trials":1208,"activeCount":98},[],{"trials":1210,"activeCount":98},[],{"intervention":1212,"totalTrials":144,"cells":1213},"Hydrogen Gas",{"EARLY_PHASE1":1214,"PHASE1":1216,"PHASE2":1227,"PHASE3":1229,"PHASE4":1231,"NA":1233},{"trials":1215,"activeCount":98},[],{"trials":1217,"activeCount":144,"soonestReadout":253},[1218],{"nctId":1219,"briefTitle":1220,"status":110,"phases":1221,"primaryCompletion":253,"completion":1222,"start":1223,"enrollment":1224,"conditions":1225,"interventions":1226},"NCT07411911","Hydrogen In Neonatal Encephalopathy (HIE) Trial",[86],"2031-03","2026-03",54,[1199,1198],[1212],{"trials":1228,"activeCount":98},[],{"trials":1230,"activeCount":98},[],{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[],{"intervention":70,"totalTrials":1236,"cells":1237},6,{"EARLY_PHASE1":1238,"PHASE1":1240,"PHASE2":1242,"PHASE3":1244,"PHASE4":1257,"NA":1268},{"trials":1239,"activeCount":98},[],{"trials":1241,"activeCount":98},[],{"trials":1243,"activeCount":98},[],{"trials":1245,"activeCount":98},[1246],{"nctId":1247,"briefTitle":1248,"status":565,"phases":1249,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":1253,"interventions":1255},"NCT01152021","Comparing Safety and Efficacy of Dexmedetomidine and Propofol",[88],"2014-07","2011-08",15,[1254],"Safety and Efficacy of Sedation Medications",[70,1256],"Propofol",{"trials":1258,"activeCount":98},[1259],{"nctId":1260,"briefTitle":1261,"status":201,"phases":1262,"primaryCompletion":1263,"completion":1263,"start":1264,"enrollment":1265,"conditions":1266,"interventions":1267},"NCT04798482","Effect of Dexmedetomidine of Gastrointestinal Motility",[89],"2022-11-15","2021-09-14",22,[35],[70],{"trials":1269,"activeCount":144,"soonestReadout":69},[1270,1286,1296,1304],{"nctId":1271,"briefTitle":1272,"status":201,"phases":1273,"primaryCompletion":1274,"completion":462,"start":1275,"enrollment":463,"conditions":1276,"interventions":1282},"NCT06326983","Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery",[90],"2026-01-30","2024-05-09",[1277,1278,1279,1280,35,1281],"Tonsillitis","Post-operative Nausea and Vomiting (PONV)","Emergence Delirium","Opioid Analgesic Adverse Reaction","Pain",[70,1283,1284,1285],"Acetaminophen","Ketorolac","Morphine",{"nctId":1287,"briefTitle":1288,"status":201,"phases":1289,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1293,"interventions":1295},"NCT02354378","A Pilot Study to Assess the Amnesic Properties of Dexmedetomidine in Pediatric Patients",[],"2015-03","2012-08",84,[1294,70],"Memory",[70],{"nctId":1297,"briefTitle":1298,"status":565,"phases":1299,"primaryCompletion":1300,"completion":1300,"start":1301,"enrollment":393,"conditions":1302,"interventions":1303},"NCT00909935","The Pharmacokinetics of Dexmedetomidine in Children",[],"2013-08","2011-04",[256],[70],{"nctId":67,"briefTitle":68,"status":125,"phases":1305,"primaryCompletion":69,"completion":1306,"start":1307,"enrollment":1136,"conditions":1308,"interventions":1310},[],"2026-12-01","2019-02-08",[1309],"Drug Effect",[70,1311,1312,1285],"Fentanyl","Midazolam",{"intervention":1285,"totalTrials":133,"cells":1314},{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1321,"PHASE4":1323,"NA":1325},{"trials":1316,"activeCount":98},[],{"trials":1318,"activeCount":98},[],{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":98},[],{"trials":1324,"activeCount":98},[],{"trials":1326,"activeCount":144,"soonestReadout":69},[1327,1331],{"nctId":1271,"briefTitle":1272,"status":201,"phases":1328,"primaryCompletion":1274,"completion":462,"start":1275,"enrollment":463,"conditions":1329,"interventions":1330},[90],[1277,1278,1279,1280,35,1281],[70,1283,1284,1285],{"nctId":67,"briefTitle":68,"status":125,"phases":1332,"primaryCompletion":69,"completion":1306,"start":1307,"enrollment":1136,"conditions":1333,"interventions":1334},[],[1309],[70,1311,1312,1285],{"intervention":143,"totalTrials":144,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1341,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1338,"activeCount":98},[],{"trials":1340,"activeCount":98},[],{"trials":1342,"activeCount":98},[],{"trials":1344,"activeCount":98},[],{"trials":1346,"activeCount":98},[],{"trials":1348,"activeCount":144,"soonestReadout":112},[1349],{"nctId":137,"briefTitle":138,"status":110,"phases":1350,"primaryCompletion":112,"completion":112,"start":113,"enrollment":140,"conditions":1351,"interventions":1352},[],[116,117,118],[143,93,132],{"intervention":1354,"totalTrials":144,"cells":1355},"whole genome sequencing or whole exome sequencing",{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1366},{"trials":1357,"activeCount":98},[],{"trials":1359,"activeCount":98},[],{"trials":1361,"activeCount":98},[],{"trials":1363,"activeCount":98},[],{"trials":1365,"activeCount":98},[],{"trials":1367,"activeCount":144,"soonestReadout":1372},[1368],{"nctId":1369,"briefTitle":1370,"status":125,"phases":1371,"primaryCompletion":1372,"completion":1372,"start":1373,"enrollment":1374,"conditions":1375,"interventions":1378},"NCT04770519","Genetic Studies of Strabismus, Nystagmus, and Associated Disorders",[],"2030-12","2021-09-03",400,[1376,1377],"Strabismus","Nystagmus, Congenital",[1354],{"intervention":56,"totalTrials":144,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1387,"PHASE4":1389,"NA":1391},{"trials":1382,"activeCount":98},[],{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[],{"trials":1388,"activeCount":98},[],{"trials":1390,"activeCount":98},[],{"trials":1392,"activeCount":144,"soonestReadout":55},[1393],{"nctId":53,"briefTitle":54,"status":110,"phases":1394,"primaryCompletion":55,"completion":74,"start":1395,"enrollment":1055,"conditions":1396,"interventions":1398},[],"2025-02",[1397],"ADHD",[56],{"intervention":79,"totalTrials":144,"cells":1400},{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1407,"PHASE4":1409,"NA":1411},{"trials":1402,"activeCount":98},[],{"trials":1404,"activeCount":98},[],{"trials":1406,"activeCount":98},[],{"trials":1408,"activeCount":98},[],{"trials":1410,"activeCount":98},[],{"trials":1412,"activeCount":144,"soonestReadout":74},[1413],{"nctId":77,"briefTitle":78,"status":999,"phases":1414,"primaryCompletion":74,"completion":74,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1420},[90],"2018-01-01",300,[1418,1419],"Disorders of Sex Development","Hypospadias",[79],{"intervention":1422,"totalTrials":144,"cells":1423},"Exome and\u002For whole genome sequencing",{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1432,"NA":1434},{"trials":1425,"activeCount":98},[],{"trials":1427,"activeCount":98},[],{"trials":1429,"activeCount":98},[],{"trials":1431,"activeCount":98},[],{"trials":1433,"activeCount":98},[],{"trials":1435,"activeCount":144,"soonestReadout":1372},[1436],{"nctId":1437,"briefTitle":1438,"status":125,"phases":1439,"primaryCompletion":1372,"completion":1372,"start":1440,"enrollment":1441,"conditions":1442,"interventions":1444},"NCT01858285","Genetics of Epilepsy and Related Disorders",[],"2010-11",5000,[32,1443],"Epileptic Encephalopathy",[1422],{"intervention":51,"totalTrials":144,"cells":1446},{"EARLY_PHASE1":1447,"PHASE1":1449,"PHASE2":1451,"PHASE3":1453,"PHASE4":1455,"NA":1457},{"trials":1448,"activeCount":98},[],{"trials":1450,"activeCount":98},[],{"trials":1452,"activeCount":98},[],{"trials":1454,"activeCount":98},[],{"trials":1456,"activeCount":98},[],{"trials":1458,"activeCount":144,"soonestReadout":50},[1459],{"nctId":48,"briefTitle":49,"status":125,"phases":1460,"primaryCompletion":50,"completion":50,"start":1461,"enrollment":1055,"conditions":1462,"interventions":1463},[],"2018-07-12",[1309],[51],{"intervention":1465,"totalTrials":144,"cells":1466},"Bupivacaine liposome injectable suspension",{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1473,"PHASE4":1475,"NA":1477},{"trials":1468,"activeCount":98},[],{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[],{"trials":1474,"activeCount":98},[],{"trials":1476,"activeCount":98},[],{"trials":1478,"activeCount":144,"soonestReadout":1483},[1479],{"nctId":1480,"briefTitle":1481,"status":125,"phases":1482,"primaryCompletion":1483,"completion":1484,"start":1485,"enrollment":1486,"conditions":1487,"interventions":1490},"NCT06471348","Postoperative Pain Control in AIS Using Liposomal Bupivacaine vs. 0.25% Bupivacaine With Epinephrine",[90],"2027-08-15","2028-08-31","2025-08-15",128,[1488,1489],"Post Operative Pain","Spinal Fusion",[1465,1491],"Bupivacaine Hydrochloride and Epinephrine",{"intervention":1491,"totalTrials":144,"cells":1493},{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1502,"NA":1504},{"trials":1495,"activeCount":98},[],{"trials":1497,"activeCount":98},[],{"trials":1499,"activeCount":98},[],{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[],{"trials":1505,"activeCount":144,"soonestReadout":1483},[1506],{"nctId":1480,"briefTitle":1481,"status":125,"phases":1507,"primaryCompletion":1483,"completion":1484,"start":1485,"enrollment":1486,"conditions":1508,"interventions":1509},[90],[1488,1489],[1465,1491],{"intervention":1511,"totalTrials":144,"cells":1512},"Genomic Sequencing",{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1523},{"trials":1514,"activeCount":98},[],{"trials":1516,"activeCount":98},[],{"trials":1518,"activeCount":98},[],{"trials":1520,"activeCount":98},[],{"trials":1522,"activeCount":98},[],{"trials":1524,"activeCount":144,"soonestReadout":1529},[1525],{"nctId":1526,"briefTitle":1527,"status":125,"phases":1528,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":1532,"interventions":1535},"NCT06701084","Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis",[90],"2029-11","2021-09-02",600,[1533,1534],"Neonatal Epilepsy","Infantile Epilepsy",[1511],{"intervention":1311,"totalTrials":144,"cells":1537},{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1542,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1539,"activeCount":98},[],{"trials":1541,"activeCount":98},[],{"trials":1543,"activeCount":98},[],{"trials":1545,"activeCount":98},[],{"trials":1547,"activeCount":98},[],{"trials":1549,"activeCount":144,"soonestReadout":69},[1550],{"nctId":67,"briefTitle":68,"status":125,"phases":1551,"primaryCompletion":69,"completion":1306,"start":1307,"enrollment":1136,"conditions":1552,"interventions":1553},[],[1309],[70,1311,1312,1285],{"intervention":1312,"totalTrials":144,"cells":1555},{"EARLY_PHASE1":1556,"PHASE1":1558,"PHASE2":1560,"PHASE3":1562,"PHASE4":1564,"NA":1566},{"trials":1557,"activeCount":98},[],{"trials":1559,"activeCount":98},[],{"trials":1561,"activeCount":98},[],{"trials":1563,"activeCount":98},[],{"trials":1565,"activeCount":98},[],{"trials":1567,"activeCount":144,"soonestReadout":69},[1568],{"nctId":67,"briefTitle":68,"status":125,"phases":1569,"primaryCompletion":69,"completion":1306,"start":1307,"enrollment":1136,"conditions":1570,"interventions":1571},[],[1309],[70,1311,1312,1285],{"intervention":1573,"totalTrials":133,"cells":1574},"Tranexamic Acid",{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1589,"PHASE4":1591,"NA":1604},{"trials":1576,"activeCount":98},[],{"trials":1578,"activeCount":98},[],{"trials":1580,"activeCount":98},[1581],{"nctId":1582,"briefTitle":1583,"status":201,"phases":1584,"primaryCompletion":1585,"completion":1585,"start":907,"enrollment":190,"conditions":1586,"interventions":1588},"NCT01813058","Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?",[86,87],"2016-05",[1587],"Adolescent Idiopathic Scoliosis",[1573],{"trials":1590,"activeCount":98},[],{"trials":1592,"activeCount":98},[1593],{"nctId":1594,"briefTitle":1595,"status":1596,"phases":1597,"primaryCompletion":1598,"completion":1598,"start":1599,"enrollment":98,"conditions":1600,"interventions":1602},"NCT03823417","The Effectiveness Of Intravenous TXA on Reducing Perioperative Blood Loss For Patients Undergoing PAO","WITHDRAWN",[89],"2019-07-23","2019-07",[1601],"Bleeding",[1573,1603],"Normal saline",{"trials":1605,"activeCount":98},[],{"intervention":1607,"totalTrials":144,"cells":1608},"Amoxicillin",{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1617,"NA":1628},{"trials":1610,"activeCount":98},[],{"trials":1612,"activeCount":98},[],{"trials":1614,"activeCount":98},[],{"trials":1616,"activeCount":98},[],{"trials":1618,"activeCount":98},[1619],{"nctId":1620,"briefTitle":1621,"status":1596,"phases":1622,"primaryCompletion":1623,"completion":1623,"start":1624,"enrollment":98,"conditions":1625,"interventions":1627},"NCT04057014","Immediate Versus Delayed Treatment of Odontogenic Infections",[89],"2020-10-02","2020-10",[1626],"Focal Infection, Dental",[1607],{"trials":1629,"activeCount":98},[],{"intervention":1631,"totalTrials":144,"cells":1632},"Deferoxamine",{"EARLY_PHASE1":1633,"PHASE1":1635,"PHASE2":1637,"PHASE3":1639,"PHASE4":1641,"NA":1655},{"trials":1634,"activeCount":98},[],{"trials":1636,"activeCount":98},[],{"trials":1638,"activeCount":98},[],{"trials":1640,"activeCount":98},[],{"trials":1642,"activeCount":98},[1643],{"nctId":1644,"briefTitle":1645,"status":201,"phases":1646,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":1252,"conditions":1650,"interventions":1653},"NCT00749515","Pilot Study for Patients With Poor Response to Deferasirox",[89],"2008-10","2008-11","2008-03",[1651,1652,616],"Transfusion-dependent Hemachromatosis","Thalassemia Major",[1631,1654],"Deferasirox",{"trials":1656,"activeCount":98},[],{"intervention":1654,"totalTrials":144,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1667,"NA":1673},{"trials":1660,"activeCount":98},[],{"trials":1662,"activeCount":98},[],{"trials":1664,"activeCount":98},[],{"trials":1666,"activeCount":98},[],{"trials":1668,"activeCount":98},[1669],{"nctId":1644,"briefTitle":1645,"status":201,"phases":1670,"primaryCompletion":1647,"completion":1648,"start":1649,"enrollment":1252,"conditions":1671,"interventions":1672},[89],[1651,1652,616],[1631,1654],{"trials":1674,"activeCount":98},[],{"intervention":1676,"totalTrials":144,"cells":1677},"F-18 Fluorodeoxyglucose",{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1682,"PHASE3":1684,"PHASE4":1686,"NA":1697},{"trials":1679,"activeCount":98},[],{"trials":1681,"activeCount":98},[],{"trials":1683,"activeCount":98},[],{"trials":1685,"activeCount":98},[],{"trials":1687,"activeCount":98},[1688],{"nctId":1689,"briefTitle":1690,"status":1596,"phases":1691,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":98,"conditions":1694,"interventions":1696},"NCT03107325","Biokinetics Study for F-18 FDG in Pediatric Molecular Imaging",[89],"2020-10-01","2019-02-01",[1695],"Childhood Neoplasm",[1676],{"trials":1698,"activeCount":98},[],{"intervention":1700,"totalTrials":144,"cells":1701},"Bilateral erector spinae blocks using ropivacaine",{"EARLY_PHASE1":1702,"PHASE1":1704,"PHASE2":1706,"PHASE3":1708,"PHASE4":1710,"NA":1722},{"trials":1703,"activeCount":98},[],{"trials":1705,"activeCount":98},[],{"trials":1707,"activeCount":98},[],{"trials":1709,"activeCount":98},[],{"trials":1711,"activeCount":98},[1712],{"nctId":1713,"briefTitle":1714,"status":201,"phases":1715,"primaryCompletion":1716,"completion":1716,"start":1717,"enrollment":1718,"conditions":1719,"interventions":1721},"NCT04567407","Bilateral Continuous Erector Spinae Blocks for Post-Sternotomy Pain Management",[89],"2022-01-22","2020-09-22",45,[1720],"Postoperative Pain",[1700],{"trials":1723,"activeCount":98},[],{"intervention":1725,"totalTrials":144,"cells":1726},"10 cc of 0.25% bupivacaine hydrochloride with 1:200,000 epinephrine",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1733,"PHASE4":1735,"NA":1750},{"trials":1728,"activeCount":98},[],{"trials":1730,"activeCount":98},[],{"trials":1732,"activeCount":98},[],{"trials":1734,"activeCount":98},[],{"trials":1736,"activeCount":98},[1737],{"nctId":1738,"briefTitle":1739,"status":201,"phases":1740,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":128,"conditions":1743,"interventions":1748},"NCT06450028","Lidocaine Versus Bupivacaine in Orthognathic Surgery",[89],"2025-11-30","2024-07-26",[1744,1745,1746,1747],"Pain, Postoperative","Numbness","Temperature Sensation","Perception of Touch",[1725,1749],"6.8 cc of 2% lidocaine hydrochloride with 1:100,000 epinephrine",{"trials":1751,"activeCount":98},[],{"intervention":1749,"totalTrials":144,"cells":1753},{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1768},{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[],{"trials":1759,"activeCount":98},[],{"trials":1761,"activeCount":98},[],{"trials":1763,"activeCount":98},[1764],{"nctId":1738,"briefTitle":1739,"status":201,"phases":1765,"primaryCompletion":1741,"completion":1741,"start":1742,"enrollment":128,"conditions":1766,"interventions":1767},[89],[1744,1745,1746,1747],[1725,1749],{"trials":1769,"activeCount":98},[],{"intervention":1771,"totalTrials":144,"cells":1772},"Extended Release Methylphenidate",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1793},{"trials":1774,"activeCount":98},[],{"trials":1776,"activeCount":98},[],{"trials":1778,"activeCount":98},[],{"trials":1780,"activeCount":98},[],{"trials":1782,"activeCount":98},[1783],{"nctId":1784,"briefTitle":1785,"status":201,"phases":1786,"primaryCompletion":1787,"completion":1787,"start":1788,"enrollment":1789,"conditions":1790,"interventions":1792},"NCT00323947","Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy",[89],"2007-11","2003-05",33,[1791,32],"Attention Deficit Disorder With Hyperactivity",[1771],{"trials":1794,"activeCount":98},[],{"intervention":1796,"totalTrials":144,"cells":1797},"Povidone-Iodine",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1817},{"trials":1799,"activeCount":98},[],{"trials":1801,"activeCount":98},[],{"trials":1803,"activeCount":98},[],{"trials":1805,"activeCount":98},[],{"trials":1807,"activeCount":98},[1808],{"nctId":1809,"briefTitle":1810,"status":201,"phases":1811,"primaryCompletion":1693,"completion":1812,"start":1813,"enrollment":8,"conditions":1814,"interventions":1816},"NCT02527512","Bacterial Contamination: Iodine vs Saline Irrigation in Pediatric Spine Surgery",[89],"2019-07-12","2017-07-13",[1815],"Surgical Site Infection",[1796],{"trials":1818,"activeCount":98},[],{"intervention":1820,"totalTrials":144,"cells":1821},"Budesonide\u002FFormoterol",{"EARLY_PHASE1":1822,"PHASE1":1824,"PHASE2":1826,"PHASE3":1828,"PHASE4":1830,"NA":1842},{"trials":1823,"activeCount":98},[],{"trials":1825,"activeCount":98},[],{"trials":1827,"activeCount":98},[],{"trials":1829,"activeCount":98},[],{"trials":1831,"activeCount":98},[1832],{"nctId":1833,"briefTitle":1834,"status":565,"phases":1835,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":1236,"conditions":1838,"interventions":1840},"NCT01070888","Trial on the Effect of Budesonide\u002FFormoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma",[89],"2014-04","2010-02",[1839],"Exercise Induced Asthma",[1820,1841],"Budesonide",{"trials":1843,"activeCount":98},[],{"intervention":1841,"totalTrials":144,"cells":1845},{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1850,"PHASE3":1852,"PHASE4":1854,"NA":1860},{"trials":1847,"activeCount":98},[],{"trials":1849,"activeCount":98},[],{"trials":1851,"activeCount":98},[],{"trials":1853,"activeCount":98},[],{"trials":1855,"activeCount":98},[1856],{"nctId":1833,"briefTitle":1834,"status":565,"phases":1857,"primaryCompletion":1836,"completion":1836,"start":1837,"enrollment":1236,"conditions":1858,"interventions":1859},[89],[1839],[1820,1841],{"trials":1861,"activeCount":98},[],{"intervention":1863,"totalTrials":144,"cells":1864},"Lansoprazole",{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1871,"PHASE4":1873,"NA":1886},{"trials":1866,"activeCount":98},[],{"trials":1868,"activeCount":98},[],{"trials":1870,"activeCount":98},[],{"trials":1872,"activeCount":98},[],{"trials":1874,"activeCount":98},[1875],{"nctId":1876,"briefTitle":1877,"status":565,"phases":1878,"primaryCompletion":1879,"completion":1879,"start":1880,"enrollment":133,"conditions":1881,"interventions":1885},"NCT00472186","The Effects of Reducing Stomach Acid on Post-tonsillectomy Pain",[89],"2011-02","2008-06",[1882,1883,1884],"Post-tonsillectomy Pain","Post-tonsillectomy Activity","Post-tonsillectomy Hydration",[1863],{"trials":1887,"activeCount":98},[],{"intervention":1889,"totalTrials":144,"cells":1890},"Baclofen",{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1897,"PHASE4":1899,"NA":1912},{"trials":1892,"activeCount":98},[],{"trials":1894,"activeCount":98},[],{"trials":1896,"activeCount":98},[],{"trials":1898,"activeCount":98},[],{"trials":1900,"activeCount":98},[1901],{"nctId":1902,"briefTitle":1903,"status":1596,"phases":1904,"primaryCompletion":1905,"completion":1906,"start":1907,"enrollment":98,"conditions":1908,"interventions":1911},"NCT01386255","Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy",[89],"2012-04","2012-04-30","2009-04",[1909,1910],"Cerebral Palsy","GERD",[1889],{"trials":1913,"activeCount":98},[],{"intervention":1915,"totalTrials":144,"cells":1916},"Regional Anesthesia",{"EARLY_PHASE1":1917,"PHASE1":1919,"PHASE2":1921,"PHASE3":1923,"PHASE4":1925,"NA":1937},{"trials":1918,"activeCount":98},[],{"trials":1920,"activeCount":98},[],{"trials":1922,"activeCount":98},[],{"trials":1924,"activeCount":98},[],{"trials":1926,"activeCount":98},[1927],{"nctId":1928,"briefTitle":1929,"status":201,"phases":1930,"primaryCompletion":963,"completion":963,"start":1931,"enrollment":1932,"conditions":1933,"interventions":1935},"NCT00756600","A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants",[89],"2006-10-23",643,[1934],"Inguinal Hernia",[1915,1936],"General Anesthesia",{"trials":1938,"activeCount":98},[],{"intervention":1936,"totalTrials":144,"cells":1940},{"EARLY_PHASE1":1941,"PHASE1":1943,"PHASE2":1945,"PHASE3":1947,"PHASE4":1949,"NA":1955},{"trials":1942,"activeCount":98},[],{"trials":1944,"activeCount":98},[],{"trials":1946,"activeCount":98},[],{"trials":1948,"activeCount":98},[],{"trials":1950,"activeCount":98},[1951],{"nctId":1928,"briefTitle":1929,"status":201,"phases":1952,"primaryCompletion":963,"completion":963,"start":1931,"enrollment":1932,"conditions":1953,"interventions":1954},[89],[1934],[1915,1936],{"trials":1956,"activeCount":98},[],{"intervention":1958,"totalTrials":144,"cells":1959},"high dose TXA",{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1966,"PHASE4":1968,"NA":1981},{"trials":1961,"activeCount":98},[],{"trials":1963,"activeCount":98},[],{"trials":1965,"activeCount":98},[],{"trials":1967,"activeCount":98},[],{"trials":1969,"activeCount":98},[1970],{"nctId":1971,"briefTitle":1972,"status":201,"phases":1973,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":114,"conditions":1977,"interventions":1979},"NCT02188576","The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery",[89],"2017-12","2018-01","2014-08",[1978],"Craniosynostosis",[1958,1980],"Low dose TXA",{"trials":1982,"activeCount":98},[],{"intervention":1980,"totalTrials":144,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1991,"PHASE4":1993,"NA":1999},{"trials":1986,"activeCount":98},[],{"trials":1988,"activeCount":98},[],{"trials":1990,"activeCount":98},[],{"trials":1992,"activeCount":98},[],{"trials":1994,"activeCount":98},[1995],{"nctId":1971,"briefTitle":1972,"status":201,"phases":1996,"primaryCompletion":1974,"completion":1975,"start":1976,"enrollment":114,"conditions":1997,"interventions":1998},[89],[1978],[1958,1980],{"trials":2000,"activeCount":98},[],{"intervention":576,"totalTrials":94,"cells":2002},{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2033,"PHASE4":2039,"NA":2041},{"trials":2004,"activeCount":98},[],{"trials":2006,"activeCount":98},[],{"trials":2008,"activeCount":98},[2009,2023],{"nctId":2010,"briefTitle":2011,"status":565,"phases":2012,"primaryCompletion":2013,"completion":2014,"start":2015,"enrollment":2016,"conditions":2017,"interventions":2021},"NCT02110069","A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors",[87],"2019-10-02","2020-10-27","2017-06-14",4,[2018,2019,2020],"Kaposiform Hemangioendothelioma (KHE)","Kasabach-Merritt Syndrome","Tufted Angioma",[2022,576],"Vincristine",{"nctId":2024,"briefTitle":2025,"status":1596,"phases":2026,"primaryCompletion":2027,"completion":2027,"start":2028,"enrollment":98,"conditions":2029,"interventions":2032},"NCT02365415","Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement",[87],"2018-04","2015-02",[2030,2031],"Peripheral Pulmonary Stenosis","In-stent Stenosis",[576],{"trials":2034,"activeCount":98},[2035],{"nctId":563,"briefTitle":564,"status":565,"phases":2036,"primaryCompletion":567,"completion":568,"start":569,"enrollment":570,"conditions":2037,"interventions":2038},[88],[572,573],[575,576,539],{"trials":2040,"activeCount":98},[],{"trials":2042,"activeCount":98},[],{"intervention":2044,"totalTrials":144,"cells":2045},"Xylitol syrup",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2052,"PHASE4":2063,"NA":2065},{"trials":2047,"activeCount":98},[],{"trials":2049,"activeCount":98},[],{"trials":2051,"activeCount":98},[],{"trials":2053,"activeCount":98},[2054],{"nctId":2055,"briefTitle":2056,"status":201,"phases":2057,"primaryCompletion":2058,"completion":2058,"start":1837,"enrollment":2059,"conditions":2060,"interventions":2062},"NCT01044030","Xylitol Syrup for the Prevention of Acute Otitis Media in Otitis-prone Children",[88],"2012-06",326,[2061],"Acute Otitis Media",[2044],{"trials":2064,"activeCount":98},[],{"trials":2066,"activeCount":98},[],{"intervention":2068,"totalTrials":144,"cells":2069},"Nitrous oxide gas for inhalation",{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2092,"NA":2094},{"trials":2071,"activeCount":98},[],{"trials":2073,"activeCount":98},[],{"trials":2075,"activeCount":98},[],{"trials":2077,"activeCount":98},[2078],{"nctId":2079,"briefTitle":2080,"status":1596,"phases":2081,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":98,"conditions":2084,"interventions":2090},"NCT04089852","Nitrous Oxide for Pain Management During IUD Insertion in Nulliparous Adolescent Women",[87,88],"2021-11-01","2021-06-01",[2085,2086,2087,2088,2089],"Contraceptive Devices","Long-Acting Reversible Contraception","Analgesia","Adolescent Health","Gynecology",[2068,2091],"Oxygen Gas for Inhalation",{"trials":2093,"activeCount":98},[],{"trials":2095,"activeCount":98},[],{"intervention":2091,"totalTrials":144,"cells":2097},{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2104,"PHASE4":2110,"NA":2112},{"trials":2099,"activeCount":98},[],{"trials":2101,"activeCount":98},[],{"trials":2103,"activeCount":98},[],{"trials":2105,"activeCount":98},[2106],{"nctId":2079,"briefTitle":2080,"status":1596,"phases":2107,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":98,"conditions":2108,"interventions":2109},[87,88],[2085,2086,2087,2088,2089],[2068,2091],{"trials":2111,"activeCount":98},[],{"trials":2113,"activeCount":98},[],{"intervention":2115,"totalTrials":144,"cells":2116},"Vitamin D3",{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2121,"PHASE3":2123,"PHASE4":2137,"NA":2139},{"trials":2118,"activeCount":98},[],{"trials":2120,"activeCount":98},[],{"trials":2122,"activeCount":98},[],{"trials":2124,"activeCount":98},[2125],{"nctId":2126,"briefTitle":2127,"status":2128,"phases":2129,"primaryCompletion":2130,"completion":2130,"start":2131,"enrollment":2132,"conditions":2133,"interventions":2136},"NCT03162432","High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade","UNKNOWN",[88],"2023-12-01","2017-08-01",50,[2134,2135,1057],"IBD","Ulcerative Colitis",[2115],{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"intervention":2142,"totalTrials":144,"cells":2143},"Hormone replacement therapy",{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2150,"PHASE4":2163,"NA":2165},{"trials":2145,"activeCount":98},[],{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"trials":2151,"activeCount":98},[2152],{"nctId":2153,"briefTitle":2154,"status":201,"phases":2155,"primaryCompletion":2156,"completion":2157,"start":2158,"enrollment":1002,"conditions":2159,"interventions":2161},"NCT00310791","Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa",[87,88],"2009-10","2010-12","2004-04",[2160],"Anorexia Nervosa",[2142,2162],"Dehydroepiandrosterone",{"trials":2164,"activeCount":98},[],{"trials":2166,"activeCount":98},[],{"intervention":2162,"totalTrials":144,"cells":2168},{"EARLY_PHASE1":2169,"PHASE1":2171,"PHASE2":2173,"PHASE3":2175,"PHASE4":2181,"NA":2183},{"trials":2170,"activeCount":98},[],{"trials":2172,"activeCount":98},[],{"trials":2174,"activeCount":98},[],{"trials":2176,"activeCount":98},[2177],{"nctId":2153,"briefTitle":2154,"status":201,"phases":2178,"primaryCompletion":2156,"completion":2157,"start":2158,"enrollment":1002,"conditions":2179,"interventions":2180},[87,88],[2160],[2142,2162],{"trials":2182,"activeCount":98},[],{"trials":2184,"activeCount":98},[],{"intervention":2186,"totalTrials":144,"cells":2187},"CY-1503",{"EARLY_PHASE1":2188,"PHASE1":2190,"PHASE2":2192,"PHASE3":2194,"PHASE4":2206,"NA":2208},{"trials":2189,"activeCount":98},[],{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":98},[],{"trials":2195,"activeCount":98},[2196],{"nctId":2197,"briefTitle":2198,"status":201,"phases":2199,"completion":2200,"start":2201,"enrollment":2202,"conditions":2203,"interventions":2205},"NCT00226369","Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery",[87,88],"2001-06","1997-12",242,[2204],"Congenital Heart Defects",[2186],{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[],{"intervention":2211,"totalTrials":144,"cells":2212},"Occipital Nerve Block (ONB) using lidocaine and dexamethosone",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2219,"PHASE4":2231,"NA":2233},{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":98},[],{"trials":2218,"activeCount":98},[],{"trials":2220,"activeCount":98},[2221],{"nctId":2222,"briefTitle":2223,"status":565,"phases":2224,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":19,"conditions":2227,"interventions":2229},"NCT03007420","A Prospective Controlled Treatment Trial for Post-Traumatic Headaches",[88],"2024-06-14","2018-01-02",[2228],"Post-Traumatic Headaches",[2211,2230],"Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone",{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[],{"intervention":2230,"totalTrials":144,"cells":2236},{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2241,"PHASE3":2243,"PHASE4":2249,"NA":2251},{"trials":2238,"activeCount":98},[],{"trials":2240,"activeCount":98},[],{"trials":2242,"activeCount":98},[],{"trials":2244,"activeCount":98},[2245],{"nctId":2222,"briefTitle":2223,"status":565,"phases":2246,"primaryCompletion":2225,"completion":2225,"start":2226,"enrollment":19,"conditions":2247,"interventions":2248},[88],[2228],[2211,2230],{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[],{"intervention":2254,"totalTrials":144,"cells":2255},"Sterile saline",{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2260,"PHASE3":2262,"PHASE4":2274,"NA":2276},{"trials":2257,"activeCount":98},[],{"trials":2259,"activeCount":98},[],{"trials":2261,"activeCount":98},[],{"trials":2263,"activeCount":98},[2264],{"nctId":2265,"briefTitle":2266,"status":1596,"phases":2267,"primaryCompletion":2268,"completion":74,"start":2269,"enrollment":98,"conditions":2270,"interventions":2271},"NCT02712151","Efficacy of Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy",[88],"2026-11","2024-03-01",[1744],[2254,2272,2273],"Ropivacaine 0.2%","Ropivacaine 0.5%",{"trials":2275,"activeCount":98},[],{"trials":2277,"activeCount":98},[],{"intervention":2272,"totalTrials":144,"cells":2279},{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2286,"PHASE4":2292,"NA":2294},{"trials":2281,"activeCount":98},[],{"trials":2283,"activeCount":98},[],{"trials":2285,"activeCount":98},[],{"trials":2287,"activeCount":98},[2288],{"nctId":2265,"briefTitle":2266,"status":1596,"phases":2289,"primaryCompletion":2268,"completion":74,"start":2269,"enrollment":98,"conditions":2290,"interventions":2291},[88],[1744],[2254,2272,2273],{"trials":2293,"activeCount":98},[],{"trials":2295,"activeCount":98},[],{"intervention":2273,"totalTrials":144,"cells":2297},{"EARLY_PHASE1":2298,"PHASE1":2300,"PHASE2":2302,"PHASE3":2304,"PHASE4":2310,"NA":2312},{"trials":2299,"activeCount":98},[],{"trials":2301,"activeCount":98},[],{"trials":2303,"activeCount":98},[],{"trials":2305,"activeCount":98},[2306],{"nctId":2265,"briefTitle":2266,"status":1596,"phases":2307,"primaryCompletion":2268,"completion":74,"start":2269,"enrollment":98,"conditions":2308,"interventions":2309},[88],[1744],[2254,2272,2273],{"trials":2311,"activeCount":98},[],{"trials":2313,"activeCount":98},[],{"intervention":1256,"totalTrials":144,"cells":2315},{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2320,"PHASE3":2322,"PHASE4":2328,"NA":2330},{"trials":2317,"activeCount":98},[],{"trials":2319,"activeCount":98},[],{"trials":2321,"activeCount":98},[],{"trials":2323,"activeCount":98},[2324],{"nctId":1247,"briefTitle":1248,"status":565,"phases":2325,"primaryCompletion":1250,"completion":1250,"start":1251,"enrollment":1252,"conditions":2326,"interventions":2327},[88],[1254],[70,1256],{"trials":2329,"activeCount":98},[],{"trials":2331,"activeCount":98},[],{"intervention":2333,"totalTrials":144,"cells":2334},"Alendronate",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2352,"NA":2354},{"trials":2336,"activeCount":98},[],{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[],{"trials":2342,"activeCount":98},[2343],{"nctId":2344,"briefTitle":2345,"status":201,"phases":2346,"primaryCompletion":2347,"completion":2347,"start":2348,"enrollment":1136,"conditions":2349,"interventions":2351},"NCT00277251","Alendronate Osteoporosis Study",[87,88],"2006-06","2003-03",[2350],"Glucocorticoid-Associated Osteopenia and Osteoporosis",[2333],{"trials":2353,"activeCount":98},[],{"trials":2355,"activeCount":98},[],{"intervention":2357,"totalTrials":133,"cells":2358},"Norethindrone acetate",{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2382,"PHASE4":2384,"NA":2386},{"trials":2360,"activeCount":98},[],{"trials":2362,"activeCount":98},[],{"trials":2364,"activeCount":98},[2365,2373],{"nctId":2366,"briefTitle":2367,"status":201,"phases":2368,"primaryCompletion":2369,"completion":2369,"start":1585,"enrollment":30,"conditions":2370,"interventions":2371},"NCT02542410","Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study",[87],"2018-09",[1081],[2372,2357],"Cabergoline",{"nctId":2374,"briefTitle":2375,"status":1596,"phases":2376,"primaryCompletion":2377,"completion":2378,"start":1026,"enrollment":98,"conditions":2379,"interventions":2380},"NCT04948489","IUD and Norethindrone Acetate for Treatment of Endometriosis",[87],"2028-09-01","2029-09-01",[1081],[2381],"norethindrone acetate",{"trials":2383,"activeCount":98},[],{"trials":2385,"activeCount":98},[],{"trials":2387,"activeCount":98},[],{"intervention":2389,"totalTrials":133,"cells":2390},"Omegaven",{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2407,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2392,"activeCount":98},[],{"trials":2394,"activeCount":98},[2395],{"nctId":2396,"briefTitle":2397,"status":201,"phases":2398,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":2401,"conditions":2402,"interventions":2405},"NCT00512629","Cholestasis Prevention: Efficacy of IV Fish Oil",[86],"2011-12","2007-07",19,[2403,2404],"Cholestasis","Parenteral Nutrition",[2389,2406],"Intralipid",{"trials":2408,"activeCount":98},[2409],{"nctId":2410,"briefTitle":2411,"status":1596,"phases":2412,"primaryCompletion":2413,"completion":2413,"start":2414,"enrollment":98,"conditions":2415,"interventions":2417},"NCT03127345","Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health",[87],"2023-09","2019-09",[2416],"Esophageal Atresia",[2389,2406],{"trials":2419,"activeCount":98},[],{"trials":2421,"activeCount":98},[],{"trials":2423,"activeCount":98},[],{"intervention":2406,"totalTrials":133,"cells":2425},{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2434,"PHASE3":2440,"PHASE4":2442,"NA":2444},{"trials":2427,"activeCount":98},[],{"trials":2429,"activeCount":98},[2430],{"nctId":2396,"briefTitle":2397,"status":201,"phases":2431,"primaryCompletion":2399,"completion":2399,"start":2400,"enrollment":2401,"conditions":2432,"interventions":2433},[86],[2403,2404],[2389,2406],{"trials":2435,"activeCount":98},[2436],{"nctId":2410,"briefTitle":2411,"status":1596,"phases":2437,"primaryCompletion":2413,"completion":2413,"start":2414,"enrollment":98,"conditions":2438,"interventions":2439},[87],[2416],[2389,2406],{"trials":2441,"activeCount":98},[],{"trials":2443,"activeCount":98},[],{"trials":2445,"activeCount":98},[],{"intervention":2447,"totalTrials":133,"cells":2448},"Lovaza",{"EARLY_PHASE1":2449,"PHASE1":2451,"PHASE2":2453,"PHASE3":2474,"PHASE4":2476,"NA":2478},{"trials":2450,"activeCount":98},[],{"trials":2452,"activeCount":98},[],{"trials":2454,"activeCount":98},[2455,2464],{"nctId":2456,"briefTitle":2457,"status":565,"phases":2458,"primaryCompletion":2399,"completion":2459,"start":2460,"enrollment":16,"conditions":2461,"interventions":2463},"NCT00672633","Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides",[87],"2012-03","2008-04",[2462],"Hypertriglyceridemia",[2447],{"nctId":2465,"briefTitle":2466,"status":1596,"phases":2467,"primaryCompletion":2468,"completion":2468,"start":2469,"enrollment":98,"conditions":2470,"interventions":2473},"NCT01191177","Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease",[86,87],"2012-01","2011-01",[2471,2472],"Liver Disease","Short Bowel Syndrome",[2447],{"trials":2475,"activeCount":98},[],{"trials":2477,"activeCount":98},[],{"trials":2479,"activeCount":98},[],{"intervention":2372,"totalTrials":144,"cells":2481},{"EARLY_PHASE1":2482,"PHASE1":2484,"PHASE2":2486,"PHASE3":2492,"PHASE4":2494,"NA":2496},{"trials":2483,"activeCount":98},[],{"trials":2485,"activeCount":98},[],{"trials":2487,"activeCount":98},[2488],{"nctId":2366,"briefTitle":2367,"status":201,"phases":2489,"primaryCompletion":2369,"completion":2369,"start":1585,"enrollment":30,"conditions":2490,"interventions":2491},[87],[1081],[2372,2357],{"trials":2493,"activeCount":98},[],{"trials":2495,"activeCount":98},[],{"trials":2497,"activeCount":98},[],{"intervention":2499,"totalTrials":144,"cells":2500},"nesiritide",{"EARLY_PHASE1":2501,"PHASE1":2503,"PHASE2":2505,"PHASE3":2516,"PHASE4":2518,"NA":2520},{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[],{"trials":2506,"activeCount":98},[2507],{"nctId":2508,"briefTitle":2509,"status":565,"phases":2510,"primaryCompletion":1647,"completion":1647,"start":2511,"enrollment":33,"conditions":2512,"interventions":2515},"NCT00281671","Nesiritide Use Following Cardiac Surgery in Infants",[86,87],"2006-04-08",[2513,2514],"Heart Defects, Congenital","Cardiopulmonary Bypass",[2499],{"trials":2517,"activeCount":98},[],{"trials":2519,"activeCount":98},[],{"trials":2521,"activeCount":98},[],{"intervention":2523,"totalTrials":144,"cells":2524},"Tocofersolan",{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2526,"activeCount":98},[],{"trials":2528,"activeCount":98},[],{"trials":2530,"activeCount":98},[2531],{"nctId":2532,"briefTitle":2533,"status":1596,"phases":2534,"primaryCompletion":2535,"completion":2536,"start":2537,"enrollment":98,"conditions":2538,"interventions":2540},"NCT03582384","Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children",[87],"2022-01","2023-01","2020-12",[2472,2539],"Vitamin E Deficiency",[2523],{"trials":2542,"activeCount":98},[],{"trials":2544,"activeCount":98},[],{"trials":2546,"activeCount":98},[],{"intervention":2548,"totalTrials":144,"cells":2549},"Lonafarnib, Zoledronic Acid, and Pravastatin",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2566,"PHASE4":2568,"NA":2570},{"trials":2551,"activeCount":98},[],{"trials":2553,"activeCount":98},[],{"trials":2555,"activeCount":98},[2556],{"nctId":2557,"briefTitle":2558,"status":2128,"phases":2559,"primaryCompletion":2560,"completion":2561,"start":2562,"enrollment":2563,"conditions":2564,"interventions":2565},"NCT00916747","Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria",[87],"2022-02","2023-12","2009-08",85,[1004],[2548],{"trials":2567,"activeCount":98},[],{"trials":2569,"activeCount":98},[],{"trials":2571,"activeCount":98},[],{"intervention":2573,"totalTrials":144,"cells":2574},"Caffeine citrate",{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2579,"PHASE3":2590,"PHASE4":2592,"NA":2594},{"trials":2576,"activeCount":98},[],{"trials":2578,"activeCount":98},[],{"trials":2580,"activeCount":98},[2581],{"nctId":2582,"briefTitle":2583,"status":1596,"phases":2584,"primaryCompletion":2537,"completion":2585,"start":2586,"enrollment":98,"conditions":2587,"interventions":2589},"NCT02408328","Management of Apnea in Late Preterm and Term Infants",[87],"2021-05","2020-06",[2588],"Apnea",[2573],{"trials":2591,"activeCount":98},[],{"trials":2593,"activeCount":98},[],{"trials":2595,"activeCount":98},[],{"intervention":2597,"totalTrials":144,"cells":2598},"Cabergoline 0.5 MG",{"EARLY_PHASE1":2599,"PHASE1":2601,"PHASE2":2603,"PHASE3":2614,"PHASE4":2616,"NA":2618},{"trials":2600,"activeCount":98},[],{"trials":2602,"activeCount":98},[],{"trials":2604,"activeCount":98},[2605],{"nctId":2606,"briefTitle":2607,"status":201,"phases":2608,"primaryCompletion":2609,"completion":2609,"start":2610,"enrollment":2611,"conditions":2612,"interventions":2613},"NCT03928288","Cabergoline for the Treatment of Chronic Pain Due to Endometriosis",[87],"2026-01-14","2019-12-02",129,[1081],[2597],{"trials":2615,"activeCount":98},[],{"trials":2617,"activeCount":98},[],{"trials":2619,"activeCount":98},[],{"intervention":2621,"totalTrials":144,"cells":2622},"Doxorubicin",{"EARLY_PHASE1":2623,"PHASE1":2625,"PHASE2":2627,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2624,"activeCount":98},[],{"trials":2626,"activeCount":98},[],{"trials":2628,"activeCount":98},[2629],{"nctId":2630,"briefTitle":2631,"status":1596,"phases":2632,"start":2633,"enrollment":98,"conditions":2634,"interventions":2636},"NCT00124956","Doxorubicin Pharmacokinetic (PK) Study",[86,87],"2003-06",[2635],"Cancer",[2621],{"trials":2638,"activeCount":98},[],{"trials":2640,"activeCount":98},[],{"trials":2642,"activeCount":98},[],{"intervention":2022,"totalTrials":144,"cells":2644},{"EARLY_PHASE1":2645,"PHASE1":2647,"PHASE2":2649,"PHASE3":2655,"PHASE4":2657,"NA":2659},{"trials":2646,"activeCount":98},[],{"trials":2648,"activeCount":98},[],{"trials":2650,"activeCount":98},[2651],{"nctId":2010,"briefTitle":2011,"status":565,"phases":2652,"primaryCompletion":2013,"completion":2014,"start":2015,"enrollment":2016,"conditions":2653,"interventions":2654},[87],[2018,2019,2020],[2022,576],{"trials":2656,"activeCount":98},[],{"trials":2658,"activeCount":98},[],{"trials":2660,"activeCount":98},[],{"intervention":2662,"totalTrials":144,"cells":2663},"dexamethasone",{"EARLY_PHASE1":2664,"PHASE1":2666,"PHASE2":2668,"PHASE3":2680,"PHASE4":2682,"NA":2684},{"trials":2665,"activeCount":98},[],{"trials":2667,"activeCount":98},[],{"trials":2669,"activeCount":98},[2670],{"nctId":2671,"briefTitle":2672,"status":201,"phases":2673,"primaryCompletion":2674,"completion":2674,"start":2460,"enrollment":2675,"conditions":2676,"interventions":2678},"NCT00621985","Dexamethasone Treatment of Congenital Adrenal Hyperplasia",[87],"2009-06",5,[2677],"Adrenal Hyperplasia, Congenital",[2662,2679],"Hydrocortisone",{"trials":2681,"activeCount":98},[],{"trials":2683,"activeCount":98},[],{"trials":2685,"activeCount":98},[],{"intervention":2679,"totalTrials":144,"cells":2687},{"EARLY_PHASE1":2688,"PHASE1":2690,"PHASE2":2692,"PHASE3":2698,"PHASE4":2700,"NA":2702},{"trials":2689,"activeCount":98},[],{"trials":2691,"activeCount":98},[],{"trials":2693,"activeCount":98},[2694],{"nctId":2671,"briefTitle":2672,"status":201,"phases":2695,"primaryCompletion":2674,"completion":2674,"start":2460,"enrollment":2675,"conditions":2696,"interventions":2697},[87],[2677],[2662,2679],{"trials":2699,"activeCount":98},[],{"trials":2701,"activeCount":98},[],{"trials":2703,"activeCount":98},[],{"intervention":2705,"totalTrials":144,"cells":2706},"metformin HCl",{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2711,"PHASE3":2722,"PHASE4":2724,"NA":2726},{"trials":2708,"activeCount":98},[],{"trials":2710,"activeCount":98},[],{"trials":2712,"activeCount":98},[2713],{"nctId":2714,"briefTitle":2715,"status":201,"phases":2716,"primaryCompletion":2717,"completion":2717,"start":2718,"enrollment":1252,"conditions":2719,"interventions":2721},"NCT03398824","Pilot Study of Metformin for Patients With Fanconi Anemia",[87],"2020-10-09","2018-03-29",[2720],"Fanconi Anemia",[2705],{"trials":2723,"activeCount":98},[],{"trials":2725,"activeCount":98},[],{"trials":2727,"activeCount":98},[],{"intervention":2729,"totalTrials":144,"cells":2730},"MPC; rexlemestrocel-L",{"EARLY_PHASE1":2731,"PHASE1":2733,"PHASE2":2735,"PHASE3":2747,"PHASE4":2749,"NA":2751},{"trials":2732,"activeCount":98},[],{"trials":2734,"activeCount":98},[],{"trials":2736,"activeCount":98},[2737],{"nctId":2738,"briefTitle":2739,"status":2128,"phases":2740,"primaryCompletion":2741,"completion":579,"start":2742,"enrollment":2401,"conditions":2743,"interventions":2746},"NCT03079401","Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle",[86,87],"2022-12-19","2017-11-27",[2744,2745],"Hypoplastic Left Heart Syndrome","Atrioventricular Canal",[2729],{"trials":2748,"activeCount":98},[],{"trials":2750,"activeCount":98},[],{"trials":2752,"activeCount":98},[],{"intervention":2754,"totalTrials":144,"cells":2755},"Recombinant Human Insulin Growth Factor 1",{"EARLY_PHASE1":2756,"PHASE1":2758,"PHASE2":2760,"PHASE3":2771,"PHASE4":2773,"NA":2775},{"trials":2757,"activeCount":98},[],{"trials":2759,"activeCount":98},[],{"trials":2761,"activeCount":98},[2762],{"nctId":2763,"briefTitle":2764,"status":201,"phases":2765,"primaryCompletion":2766,"completion":2767,"start":907,"enrollment":1055,"conditions":2768,"interventions":2770},"NCT01777542","Treatment of Rett Syndrome With Recombinant Human IGF-1",[87],"2016-07","2016-11",[2769],"Rett Syndrome",[2754],{"trials":2772,"activeCount":98},[],{"trials":2774,"activeCount":98},[],{"trials":2776,"activeCount":98},[],{"intervention":2778,"totalTrials":144,"cells":2779},"nitric oxide",{"EARLY_PHASE1":2780,"PHASE1":2782,"PHASE2":2784,"PHASE3":2795,"PHASE4":2797,"NA":2799},{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[],{"trials":2785,"activeCount":98},[2786],{"nctId":2787,"briefTitle":2788,"status":565,"phases":2789,"primaryCompletion":1300,"completion":1300,"start":2790,"enrollment":2791,"conditions":2792,"interventions":2793},"NCT00142051","Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis",[87],"2005-04",18,[616],[2778,2794],"oxygen",{"trials":2796,"activeCount":98},[],{"trials":2798,"activeCount":98},[],{"trials":2800,"activeCount":98},[],{"intervention":2794,"totalTrials":144,"cells":2802},{"EARLY_PHASE1":2803,"PHASE1":2805,"PHASE2":2807,"PHASE3":2813,"PHASE4":2815,"NA":2817},{"trials":2804,"activeCount":98},[],{"trials":2806,"activeCount":98},[],{"trials":2808,"activeCount":98},[2809],{"nctId":2787,"briefTitle":2788,"status":565,"phases":2810,"primaryCompletion":1300,"completion":1300,"start":2790,"enrollment":2791,"conditions":2811,"interventions":2812},[87],[616],[2778,2794],{"trials":2814,"activeCount":98},[],{"trials":2816,"activeCount":98},[],{"trials":2818,"activeCount":98},[],{"intervention":2820,"totalTrials":144,"cells":2821},"Naltrexone HCl (Bulk) Powder",{"EARLY_PHASE1":2822,"PHASE1":2824,"PHASE2":2826,"PHASE3":2837,"PHASE4":2839,"NA":2841},{"trials":2823,"activeCount":98},[],{"trials":2825,"activeCount":98},[],{"trials":2827,"activeCount":98},[2828],{"nctId":2829,"briefTitle":2830,"status":201,"phases":2831,"primaryCompletion":2832,"completion":2832,"start":2833,"enrollment":1718,"conditions":2834,"interventions":2836},"NCT03447782","Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children",[86,87],"2020-11-20","2018-07-23",[2835],"New Daily Persistent Headache (NDPH)",[2820],{"trials":2838,"activeCount":98},[],{"trials":2840,"activeCount":98},[],{"trials":2842,"activeCount":98},[],{"intervention":2844,"totalTrials":144,"cells":2845},"Epinephrine 0.5 mcg\u002Fkg",{"EARLY_PHASE1":2846,"PHASE1":2848,"PHASE2":2850,"PHASE3":2862,"PHASE4":2864,"NA":2866},{"trials":2847,"activeCount":98},[],{"trials":2849,"activeCount":98},[],{"trials":2851,"activeCount":98},[2852],{"nctId":2853,"briefTitle":2854,"status":565,"phases":2855,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":1252,"conditions":2858,"interventions":2860},"NCT05327556","Epinephrine in the Pediatric Intensive Care Unit: A Dose-Effect Trial",[87],"2025-05-16","2023-02-08",[2859],"Hypotension",[2844,2861],"Epinephrine 1 mcg\u002Fkg",{"trials":2863,"activeCount":98},[],{"trials":2865,"activeCount":98},[],{"trials":2867,"activeCount":98},[],{"intervention":2861,"totalTrials":144,"cells":2869},{"EARLY_PHASE1":2870,"PHASE1":2872,"PHASE2":2874,"PHASE3":2880,"PHASE4":2882,"NA":2884},{"trials":2871,"activeCount":98},[],{"trials":2873,"activeCount":98},[],{"trials":2875,"activeCount":98},[2876],{"nctId":2853,"briefTitle":2854,"status":565,"phases":2877,"primaryCompletion":2856,"completion":2856,"start":2857,"enrollment":1252,"conditions":2878,"interventions":2879},[87],[2859],[2844,2861],{"trials":2881,"activeCount":98},[],{"trials":2883,"activeCount":98},[],{"trials":2885,"activeCount":98},[],{"intervention":2887,"totalTrials":144,"cells":2888},"crystalline cholesterol oil-based suspension",{"EARLY_PHASE1":2889,"PHASE1":2891,"PHASE2":2893,"PHASE3":2906,"PHASE4":2908,"NA":2910},{"trials":2890,"activeCount":98},[],{"trials":2892,"activeCount":98},[],{"trials":2894,"activeCount":98},[2895],{"nctId":2896,"briefTitle":2897,"status":201,"phases":2898,"primaryCompletion":2899,"completion":2900,"start":2901,"enrollment":2902,"conditions":2903,"interventions":2905},"NCT00272844","Treatment of the Cholesterol Defect in Smith-Lemli-Opitz Syndrome",[86,87],"2011-06","2011-07","1998-01",23,[2904],"Smith-Lemli-Opitz Syndrome",[2887],{"trials":2907,"activeCount":98},[],{"trials":2909,"activeCount":98},[],{"trials":2911,"activeCount":98},[],{"intervention":2913,"totalTrials":144,"cells":2914},"HDM sublingual Immunotherapy",{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2931,"PHASE4":2933,"NA":2935},{"trials":2916,"activeCount":98},[],{"trials":2918,"activeCount":98},[],{"trials":2920,"activeCount":98},[2921],{"nctId":2922,"briefTitle":2923,"status":1596,"phases":2924,"primaryCompletion":2925,"completion":2926,"start":2927,"enrollment":98,"conditions":2928,"interventions":2930},"NCT05113394","Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy",[87],"2028-02-01","2029-08-01","2027-02-01",[18,2929],"Allergy",[2913],{"trials":2932,"activeCount":98},[],{"trials":2934,"activeCount":98},[],{"trials":2936,"activeCount":98},[],{"intervention":2938,"totalTrials":144,"cells":2939},"RAD001",{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2957,"PHASE4":2959,"NA":2961},{"trials":2941,"activeCount":98},[],{"trials":2943,"activeCount":98},[],{"trials":2945,"activeCount":98},[2946],{"nctId":2947,"briefTitle":2948,"status":201,"phases":2949,"primaryCompletion":2950,"completion":2951,"start":2952,"enrollment":2953,"conditions":2954,"interventions":2956},"NCT02991807","RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome",[86,87],"2021-02-18","2021-12-22","2017-06-12",46,[2955,803],"PTEN Gene Mutation",[2938],{"trials":2958,"activeCount":98},[],{"trials":2960,"activeCount":98},[],{"trials":2962,"activeCount":98},[],{"intervention":2964,"totalTrials":144,"cells":2965},"70% ethanol",{"EARLY_PHASE1":2966,"PHASE1":2968,"PHASE2":2970,"PHASE3":2980,"PHASE4":2982,"NA":2984},{"trials":2967,"activeCount":98},[],{"trials":2969,"activeCount":98},[],{"trials":2971,"activeCount":98},[2972],{"nctId":2973,"briefTitle":2974,"status":1596,"phases":2975,"primaryCompletion":2058,"completion":2976,"start":1879,"enrollment":98,"conditions":2977,"interventions":2979},"NCT01263574","Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome",[87],"2012-09",[2978,2472],"Catheter Related Infections",[2964],{"trials":2981,"activeCount":98},[],{"trials":2983,"activeCount":98},[],{"trials":2985,"activeCount":98},[],{"intervention":725,"totalTrials":144,"cells":2987},{"EARLY_PHASE1":2988,"PHASE1":2990,"PHASE2":2992,"PHASE3":2998,"PHASE4":3000,"NA":3002},{"trials":2989,"activeCount":98},[],{"trials":2991,"activeCount":98},[],{"trials":2993,"activeCount":98},[2994],{"nctId":716,"briefTitle":717,"status":201,"phases":2995,"primaryCompletion":719,"completion":719,"start":720,"enrollment":721,"conditions":2996,"interventions":2997},[87],[723],[725,657],{"trials":2999,"activeCount":98},[],{"trials":3001,"activeCount":98},[],{"trials":3003,"activeCount":98},[],{"intervention":3005,"totalTrials":144,"cells":3006},"Bevacizumab",{"EARLY_PHASE1":3007,"PHASE1":3009,"PHASE2":3011,"PHASE3":3020,"PHASE4":3022,"NA":3024},{"trials":3008,"activeCount":98},[],{"trials":3010,"activeCount":98},[],{"trials":3012,"activeCount":98},[3013],{"nctId":3014,"briefTitle":3015,"status":201,"phases":3016,"primaryCompletion":1001,"completion":1001,"start":1647,"enrollment":2132,"conditions":3017,"interventions":3019},"NCT00891527","Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis",[86,87],[3018],"Pulmonary Veno Occlusive Disease",[3005],{"trials":3021,"activeCount":98},[],{"trials":3023,"activeCount":98},[],{"trials":3025,"activeCount":98},[],{"intervention":3027,"totalTrials":144,"cells":3028},"danazol",{"EARLY_PHASE1":3029,"PHASE1":3031,"PHASE2":3033,"PHASE3":3041,"PHASE4":3043,"NA":3045},{"trials":3030,"activeCount":98},[],{"trials":3032,"activeCount":98},[],{"trials":3034,"activeCount":98},[3035],{"nctId":3036,"briefTitle":3037,"status":565,"phases":3038,"primaryCompletion":506,"completion":506,"start":943,"enrollment":2675,"conditions":3039,"interventions":3040},"NCT01001598","Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita",[86,87],[2720,552],[3027],{"trials":3042,"activeCount":98},[],{"trials":3044,"activeCount":98},[],{"trials":3046,"activeCount":98},[],{"intervention":3048,"totalTrials":144,"cells":3049},"Norethindrone acetate + estrogens",{"EARLY_PHASE1":3050,"PHASE1":3052,"PHASE2":3054,"PHASE3":3066,"PHASE4":3068,"NA":3070},{"trials":3051,"activeCount":98},[],{"trials":3053,"activeCount":98},[],{"trials":3055,"activeCount":98},[3056],{"nctId":3057,"briefTitle":3058,"status":201,"phases":3059,"primaryCompletion":3060,"completion":3061,"start":3062,"enrollment":650,"conditions":3063,"interventions":3064},"NCT00474851","The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial",[87],"2013-10","2015-01","2007-08",[1081],[3048,3065],"norethindrone acetate + placebo",{"trials":3067,"activeCount":98},[],{"trials":3069,"activeCount":98},[],{"trials":3071,"activeCount":98},[],{"intervention":3065,"totalTrials":144,"cells":3073},{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3084,"PHASE4":3086,"NA":3088},{"trials":3075,"activeCount":98},[],{"trials":3077,"activeCount":98},[],{"trials":3079,"activeCount":98},[3080],{"nctId":3057,"briefTitle":3058,"status":201,"phases":3081,"primaryCompletion":3060,"completion":3061,"start":3062,"enrollment":650,"conditions":3082,"interventions":3083},[87],[1081],[3048,3065],{"trials":3085,"activeCount":98},[],{"trials":3087,"activeCount":98},[],{"trials":3089,"activeCount":98},[],{"intervention":3091,"totalTrials":144,"cells":3092},"Lonafarnib",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3108,"PHASE4":3110,"NA":3112},{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[],{"trials":3098,"activeCount":98},[3099],{"nctId":3100,"briefTitle":3101,"status":201,"phases":3102,"primaryCompletion":1907,"completion":1907,"start":892,"enrollment":2675,"conditions":3103,"interventions":3105},"NCT00879034","A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria",[87],[1004,3104],"Hutchinson-Gilford Syndrome",[3091,3106,3107],"Zoledronic Acid","Pravastatin",{"trials":3109,"activeCount":98},[],{"trials":3111,"activeCount":98},[],{"trials":3113,"activeCount":98},[],{"intervention":3106,"totalTrials":144,"cells":3115},{"EARLY_PHASE1":3116,"PHASE1":3118,"PHASE2":3120,"PHASE3":3126,"PHASE4":3128,"NA":3130},{"trials":3117,"activeCount":98},[],{"trials":3119,"activeCount":98},[],{"trials":3121,"activeCount":98},[3122],{"nctId":3100,"briefTitle":3101,"status":201,"phases":3123,"primaryCompletion":1907,"completion":1907,"start":892,"enrollment":2675,"conditions":3124,"interventions":3125},[87],[1004,3104],[3091,3106,3107],{"trials":3127,"activeCount":98},[],{"trials":3129,"activeCount":98},[],{"trials":3131,"activeCount":98},[],{"intervention":3107,"totalTrials":144,"cells":3133},{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3138,"PHASE3":3144,"PHASE4":3146,"NA":3148},{"trials":3135,"activeCount":98},[],{"trials":3137,"activeCount":98},[],{"trials":3139,"activeCount":98},[3140],{"nctId":3100,"briefTitle":3101,"status":201,"phases":3141,"primaryCompletion":1907,"completion":1907,"start":892,"enrollment":2675,"conditions":3142,"interventions":3143},[87],[1004,3104],[3091,3106,3107],{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"trials":3149,"activeCount":98},[],{"intervention":3151,"totalTrials":144,"cells":3152},"Senicapoc",{"EARLY_PHASE1":3153,"PHASE1":3155,"PHASE2":3157,"PHASE3":3168,"PHASE4":3170,"NA":3172},{"trials":3154,"activeCount":98},[],{"trials":3156,"activeCount":98},[],{"trials":3158,"activeCount":98},[3159],{"nctId":3160,"briefTitle":3161,"status":201,"phases":3162,"primaryCompletion":3163,"completion":3163,"start":3164,"enrollment":2675,"conditions":3165,"interventions":3167},"NCT04372498","Senicapoc and Dehydrated Stomatocytosis",[86,87],"2024-02-01","2021-04-15",[3166],"Dehydrated Hereditary Stomatocytosis",[3151],{"trials":3169,"activeCount":98},[],{"trials":3171,"activeCount":98},[],{"trials":3173,"activeCount":98},[],{"intervention":3175,"totalTrials":144,"cells":3176},"Opioid",{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3181,"PHASE3":3192,"PHASE4":3194,"NA":3196},{"trials":3178,"activeCount":98},[],{"trials":3180,"activeCount":98},[],{"trials":3182,"activeCount":98},[3183],{"nctId":3184,"briefTitle":3185,"status":565,"phases":3186,"primaryCompletion":3187,"completion":3187,"start":3188,"enrollment":2902,"conditions":3189,"interventions":3191},"NCT04291599","Initial Pain Management in Pediatric Pancreatitis: Opioid vs. Non-Opioid",[87],"2025-07-24","2022-03-15",[3190],"Acute Pancreatitis",[1284,3175],{"trials":3193,"activeCount":98},[],{"trials":3195,"activeCount":98},[],{"trials":3197,"activeCount":98},[],{"intervention":3199,"totalTrials":144,"cells":3200},"divalproex sodium",{"EARLY_PHASE1":3201,"PHASE1":3203,"PHASE2":3205,"PHASE3":3215,"PHASE4":3217,"NA":3219},{"trials":3202,"activeCount":98},[],{"trials":3204,"activeCount":98},[],{"trials":3206,"activeCount":98},[3207],{"nctId":3208,"briefTitle":3209,"status":1596,"phases":3210,"primaryCompletion":3211,"completion":3211,"start":1836,"enrollment":98,"conditions":3212,"interventions":3214},"NCT02094651","Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium",[87],"2016-10",[3213],"Autism",[3199],{"trials":3216,"activeCount":98},[],{"trials":3218,"activeCount":98},[],{"trials":3220,"activeCount":98},[],{"intervention":3222,"totalTrials":144,"cells":3223},"Pulmozyme",{"EARLY_PHASE1":3224,"PHASE1":3226,"PHASE2":3228,"PHASE3":3239,"PHASE4":3241,"NA":3243},{"trials":3225,"activeCount":98},[],{"trials":3227,"activeCount":98},[],{"trials":3229,"activeCount":98},[3230],{"nctId":3231,"briefTitle":3232,"status":2128,"phases":3233,"primaryCompletion":3234,"completion":3234,"start":3235,"enrollment":128,"conditions":3236,"interventions":3238},"NCT04402944","Pulmozyme to Improve COVID-19 ARDS Outcomes",[87],"2021-12-31","2020-07-05",[3237],"COVID",[3222],{"trials":3240,"activeCount":98},[],{"trials":3242,"activeCount":98},[],{"trials":3244,"activeCount":98},[],{"intervention":3246,"totalTrials":144,"cells":3247},"Retrovirus Construct",{"EARLY_PHASE1":3248,"PHASE1":3250,"PHASE2":3260,"PHASE3":3262,"PHASE4":3264,"NA":3266},{"trials":3249,"activeCount":98},[],{"trials":3251,"activeCount":98},[3252],{"nctId":3253,"briefTitle":3254,"status":201,"phases":3255,"primaryCompletion":3256,"completion":3256,"start":3257,"enrollment":94,"conditions":3258,"interventions":3259},"NCT00272857","Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia",[86],"2007-10","2004-08",[2720],[3246],{"trials":3261,"activeCount":98},[],{"trials":3263,"activeCount":98},[],{"trials":3265,"activeCount":98},[],{"trials":3267,"activeCount":98},[],{"intervention":3269,"totalTrials":144,"cells":3270},"Concerta",{"EARLY_PHASE1":3271,"PHASE1":3273,"PHASE2":3283,"PHASE3":3285,"PHASE4":3287,"NA":3289},{"trials":3272,"activeCount":98},[],{"trials":3274,"activeCount":98},[3275],{"nctId":3276,"briefTitle":3277,"status":201,"phases":3278,"primaryCompletion":964,"completion":964,"start":3279,"enrollment":19,"conditions":3280,"interventions":3281},"NCT05650775","Biomarkers of ADHD Treatment Response",[86],"2023-02-17",[1397],[3269,3282],"Adderall-XR",{"trials":3284,"activeCount":98},[],{"trials":3286,"activeCount":98},[],{"trials":3288,"activeCount":98},[],{"trials":3290,"activeCount":98},[],{"intervention":3282,"totalTrials":144,"cells":3292},{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3301,"PHASE3":3303,"PHASE4":3305,"NA":3307},{"trials":3294,"activeCount":98},[],{"trials":3296,"activeCount":98},[3297],{"nctId":3276,"briefTitle":3277,"status":201,"phases":3298,"primaryCompletion":964,"completion":964,"start":3279,"enrollment":19,"conditions":3299,"interventions":3300},[86],[1397],[3269,3282],{"trials":3302,"activeCount":98},[],{"trials":3304,"activeCount":98},[],{"trials":3306,"activeCount":98},[],{"trials":3308,"activeCount":98},[],{"intervention":3310,"totalTrials":144,"cells":3311},"Donepezil",{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3323,"PHASE3":3325,"PHASE4":3327,"NA":3329},{"trials":3313,"activeCount":98},[],{"trials":3315,"activeCount":98},[3316],{"nctId":3317,"briefTitle":3318,"status":201,"phases":3319,"primaryCompletion":3320,"completion":3320,"start":1291,"enrollment":2791,"conditions":3321,"interventions":3322},"NCT01584076","Treatment of Residual Amblyopia With Donepezil",[86],"2021-01",[1028],[3310],{"trials":3324,"activeCount":98},[],{"trials":3326,"activeCount":98},[],{"trials":3328,"activeCount":98},[],{"trials":3330,"activeCount":98},[],{"intervention":3332,"totalTrials":144,"cells":3333},"Levodopa\u002FCarbidopa",{"EARLY_PHASE1":3334,"PHASE1":3336,"PHASE2":3347,"PHASE3":3349,"PHASE4":3351,"NA":3353},{"trials":3335,"activeCount":98},[],{"trials":3337,"activeCount":98},[3338],{"nctId":3339,"briefTitle":3340,"status":201,"phases":3341,"primaryCompletion":3342,"completion":3342,"start":3343,"enrollment":19,"conditions":3344,"interventions":3346},"NCT00829439","Study on Tolerability of Levodopa\u002FCarbidopa in Children With Angelman Syndrome",[86],"2010-06","2009-01",[3345],"Angelman Syndrome",[3332],{"trials":3348,"activeCount":98},[],{"trials":3350,"activeCount":98},[],{"trials":3352,"activeCount":98},[],{"trials":3354,"activeCount":98},[],{"intervention":3356,"totalTrials":144,"cells":3357},"Lumason",{"EARLY_PHASE1":3358,"PHASE1":3360,"PHASE2":3372,"PHASE3":3374,"PHASE4":3376,"NA":3378},{"trials":3359,"activeCount":98},[],{"trials":3361,"activeCount":98},[3362],{"nctId":3363,"briefTitle":3364,"status":2128,"phases":3365,"primaryCompletion":3366,"completion":3367,"start":3368,"enrollment":205,"conditions":3369,"interventions":3371},"NCT03653702","Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)",[86],"2024-04","2024-06","2023-10-01",[3370],"Vesico-Ureteral Reflux",[3356],{"trials":3373,"activeCount":98},[],{"trials":3375,"activeCount":98},[],{"trials":3377,"activeCount":98},[],{"trials":3379,"activeCount":98},[],{"intervention":3381,"totalTrials":144,"cells":3382},"rhIGF-1",{"EARLY_PHASE1":3383,"PHASE1":3385,"PHASE2":3394,"PHASE3":3396,"PHASE4":3398,"NA":3400},{"trials":3384,"activeCount":98},[],{"trials":3386,"activeCount":98},[3387],{"nctId":3388,"briefTitle":3389,"status":201,"phases":3390,"primaryCompletion":2976,"completion":907,"start":2157,"enrollment":3391,"conditions":3392,"interventions":3393},"NCT01253317","Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)",[86],12,[2769],[3381],{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[],{"trials":3399,"activeCount":98},[],{"trials":3401,"activeCount":98},[],{"intervention":3403,"totalTrials":144,"cells":3404},"Sulfur hexafluoride lipid-type A microspheres",{"EARLY_PHASE1":3405,"PHASE1":3407,"PHASE2":3417,"PHASE3":3419,"PHASE4":3421,"NA":3423},{"trials":3406,"activeCount":98},[],{"trials":3408,"activeCount":98},[3409],{"nctId":3410,"briefTitle":3411,"status":1596,"phases":3412,"primaryCompletion":3413,"completion":3413,"start":3413,"enrollment":98,"conditions":3414,"interventions":3416},"NCT03295656","Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis",[86],"2020-07-15",[3415],"Appendicitis Acute",[3403],{"trials":3418,"activeCount":98},[],{"trials":3420,"activeCount":98},[],{"trials":3422,"activeCount":98},[],{"trials":3424,"activeCount":98},[],{"intervention":3426,"totalTrials":144,"cells":3427},"Amiloride Solution for Inhalation",{"EARLY_PHASE1":3428,"PHASE1":3430,"PHASE2":3440,"PHASE3":3442,"PHASE4":3444,"NA":3446},{"trials":3429,"activeCount":98},[],{"trials":3431,"activeCount":98},[3432],{"nctId":3433,"briefTitle":3434,"status":201,"phases":3435,"primaryCompletion":3436,"completion":2469,"start":3437,"enrollment":16,"conditions":3438,"interventions":3439},"NCT00547053","Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis",[86],"2008-01","2006-12",[23],[3426],{"trials":3441,"activeCount":98},[],{"trials":3443,"activeCount":98},[],{"trials":3445,"activeCount":98},[],{"trials":3447,"activeCount":98},[],{"intervention":3449,"totalTrials":144,"cells":3450},"Marimastat",{"EARLY_PHASE1":3451,"PHASE1":3453,"PHASE2":3463,"PHASE3":3465,"PHASE4":3467,"NA":3469},{"trials":3452,"activeCount":98},[],{"trials":3454,"activeCount":98},[3455],{"nctId":3456,"briefTitle":3457,"status":201,"phases":3458,"completion":3256,"start":3459,"enrollment":33,"conditions":3460,"interventions":3462},"NCT00261391","Phase I Drug Trial for S\u002FE of Marimastat in Disabling Malformations When no Other Options.",[86],"2000-10",[3461],"Vascular Anomalies",[3449],{"trials":3464,"activeCount":98},[],{"trials":3466,"activeCount":98},[],{"trials":3468,"activeCount":98},[],{"trials":3470,"activeCount":98},[],{"intervention":3472,"totalTrials":2016,"cells":3473},"Ropivacaine",{"EARLY_PHASE1":3474,"PHASE1":3476,"PHASE2":3478,"PHASE3":3480,"PHASE4":3500,"NA":3510},{"trials":3475,"activeCount":98},[],{"trials":3477,"activeCount":98},[],{"trials":3479,"activeCount":98},[],{"trials":3481,"activeCount":98},[3482,3491],{"nctId":3483,"briefTitle":3484,"status":201,"phases":3485,"primaryCompletion":3486,"completion":3487,"start":3488,"enrollment":30,"conditions":3489,"interventions":3490},"NCT03936387","Bilateral Continuous Erector Spinae Blocks for Post-Sternotomy Pain Management: A Pilot Study",[88],"2019-09-01","2019-09-12","2019-07-01",[1744],[3472],{"nctId":3492,"briefTitle":3493,"status":565,"phases":3494,"primaryCompletion":3495,"completion":3495,"start":3496,"enrollment":3497,"conditions":3498,"interventions":3499},"NCT03768440","Continuous Erector Spinae Block Versus Continuous Paravertebral Block",[88],"2025-02-01","2019-04-16",34,[1744],[3472],{"trials":3501,"activeCount":98},[3502],{"nctId":3503,"briefTitle":3504,"status":1596,"phases":3505,"primaryCompletion":127,"completion":127,"start":3506,"enrollment":98,"conditions":3507,"interventions":3509},"NCT04481451","Quadratus Lumborum vs Erector Spinae Supplementary Blocks With Lumbar Plexus Blocks for Hip PAO",[89],"2020-12-01",[1744,1915,3508],"Hip Dysplasia",[3472],{"trials":3511,"activeCount":98},[3512],{"nctId":3513,"briefTitle":3514,"status":565,"phases":3515,"primaryCompletion":3516,"completion":3516,"start":3517,"enrollment":3518,"conditions":3519,"interventions":3520},"NCT02860091","Blood Ropivacaine Concentrations Following Chest Wall Nerve Block Continuous Infusion",[],"2026-05-14","2018-10-01",26,[1744],[3472],{"intervention":3522,"totalTrials":133,"cells":3523},"Imaging Time",{"EARLY_PHASE1":3524,"PHASE1":3526,"PHASE2":3528,"PHASE3":3530,"PHASE4":3532,"NA":3534},{"trials":3525,"activeCount":98},[],{"trials":3527,"activeCount":98},[],{"trials":3529,"activeCount":98},[],{"trials":3531,"activeCount":98},[],{"trials":3533,"activeCount":98},[],{"trials":3535,"activeCount":98},[3536,3545],{"nctId":3537,"briefTitle":3538,"status":201,"phases":3539,"primaryCompletion":3540,"completion":3540,"start":3541,"enrollment":9,"conditions":3542,"interventions":3544},"NCT03107195","Biokinetics Study of Tc-99m DMSA in Pediatric Molecular Imaging",[],"2021-10-06","2017-10-31",[3543],"Renal Disease",[3522],{"nctId":3546,"briefTitle":3547,"status":201,"phases":3548,"primaryCompletion":3540,"completion":3540,"start":3541,"enrollment":3391,"conditions":3549,"interventions":3551},"NCT03107247","Biokinetics Study for Tc-99m MDP in Pediatric Molecular Imaging",[],[3550],"Skeletal Injury",[3522],{"intervention":1603,"totalTrials":133,"cells":3553},{"EARLY_PHASE1":3554,"PHASE1":3556,"PHASE2":3558,"PHASE3":3560,"PHASE4":3562,"NA":3568},{"trials":3555,"activeCount":98},[],{"trials":3557,"activeCount":98},[],{"trials":3559,"activeCount":98},[],{"trials":3561,"activeCount":98},[],{"trials":3563,"activeCount":98},[3564],{"nctId":1594,"briefTitle":1595,"status":1596,"phases":3565,"primaryCompletion":1598,"completion":1598,"start":1599,"enrollment":98,"conditions":3566,"interventions":3567},[89],[1601],[1573,1603],{"trials":3569,"activeCount":98},[3570],{"nctId":3571,"briefTitle":3572,"status":201,"phases":3573,"primaryCompletion":3574,"completion":3574,"start":3211,"enrollment":3575,"conditions":3576,"interventions":3577},"NCT02703090","Near Infrared Spectroscopy Cortical Response to Noxious and Auditory Stimuli in Subjects Under General Anesthesia",[90],"2020-03-10",44,[35,1281],[3578,1603],"Remifentanil",{"intervention":3580,"totalTrials":133,"cells":3581},"Insulin",{"EARLY_PHASE1":3582,"PHASE1":3584,"PHASE2":3586,"PHASE3":3588,"PHASE4":3601,"NA":3603},{"trials":3583,"activeCount":98},[],{"trials":3585,"activeCount":98},[],{"trials":3587,"activeCount":98},[],{"trials":3589,"activeCount":98},[3590],{"nctId":3591,"briefTitle":3592,"status":201,"phases":3593,"primaryCompletion":3594,"completion":3595,"start":1905,"enrollment":3596,"conditions":3597,"interventions":3600},"NCT01565941","Heart And Lung Failure - Pediatric INsulin Titration Trial",[88],"2016-09","2018-02",713,[3598,3599],"Heart Failure","Respiratory Failure",[3580,3580],{"trials":3602,"activeCount":98},[],{"trials":3604,"activeCount":98},[3605],{"nctId":3606,"briefTitle":3607,"status":201,"phases":3608,"primaryCompletion":2058,"completion":3609,"start":3610,"enrollment":3611,"conditions":3612,"interventions":3614},"NCT00443599","SPECS: Safe Pediatric Euglycemia in Cardiac Surgery",[90],"2014-01","2006-11",989,[2513,3613],"Hyperglycemia",[3580],{"intervention":1284,"totalTrials":133,"cells":3616},{"EARLY_PHASE1":3617,"PHASE1":3619,"PHASE2":3621,"PHASE3":3627,"PHASE4":3629,"NA":3631},{"trials":3618,"activeCount":98},[],{"trials":3620,"activeCount":98},[],{"trials":3622,"activeCount":98},[3623],{"nctId":3184,"briefTitle":3185,"status":565,"phases":3624,"primaryCompletion":3187,"completion":3187,"start":3188,"enrollment":2902,"conditions":3625,"interventions":3626},[87],[3190],[1284,3175],{"trials":3628,"activeCount":98},[],{"trials":3630,"activeCount":98},[],{"trials":3632,"activeCount":98},[3633],{"nctId":1271,"briefTitle":1272,"status":201,"phases":3634,"primaryCompletion":1274,"completion":462,"start":1275,"enrollment":463,"conditions":3635,"interventions":3636},[90],[1277,1278,1279,1280,35,1281],[70,1283,1284,1285],{"intervention":3638,"totalTrials":144,"cells":3639},"clotrimazole",{"EARLY_PHASE1":3640,"PHASE1":3642,"PHASE2":3644,"PHASE3":3646,"PHASE4":3648,"NA":3650},{"trials":3641,"activeCount":98},[],{"trials":3643,"activeCount":98},[],{"trials":3645,"activeCount":98},[],{"trials":3647,"activeCount":98},[],{"trials":3649,"activeCount":98},[],{"trials":3651,"activeCount":98},[3652],{"nctId":3653,"briefTitle":3654,"status":201,"phases":3655,"completion":3656,"start":3657,"enrollment":1136,"conditions":3658,"interventions":3660},"NCT00004404","Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes",[90],"2002-09","1997-04",[3659],"Sickle Cell Anemia",[3638,3661],"hydroxyurea",{"intervention":3661,"totalTrials":144,"cells":3663},{"EARLY_PHASE1":3664,"PHASE1":3666,"PHASE2":3668,"PHASE3":3670,"PHASE4":3672,"NA":3674},{"trials":3665,"activeCount":98},[],{"trials":3667,"activeCount":98},[],{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[],{"trials":3675,"activeCount":98},[3676],{"nctId":3653,"briefTitle":3654,"status":201,"phases":3677,"completion":3656,"start":3657,"enrollment":1136,"conditions":3678,"interventions":3679},[90],[3659],[3638,3661],{"intervention":3681,"totalTrials":144,"cells":3682},"Tc-99M-MAG3",{"EARLY_PHASE1":3683,"PHASE1":3685,"PHASE2":3687,"PHASE3":3689,"PHASE4":3691,"NA":3693},{"trials":3684,"activeCount":98},[],{"trials":3686,"activeCount":98},[],{"trials":3688,"activeCount":98},[],{"trials":3690,"activeCount":98},[],{"trials":3692,"activeCount":98},[],{"trials":3694,"activeCount":98},[3695],{"nctId":3696,"briefTitle":3697,"status":201,"phases":3698,"primaryCompletion":3540,"completion":3540,"start":2226,"enrollment":2791,"conditions":3699,"interventions":3700},"NCT03107286","Biokinetics Study for Tc-99m MAG3 in Pediatric Molecular Imaging",[],[3543],[3681],{"intervention":3702,"totalTrials":144,"cells":3703},"Pegvaliase",{"EARLY_PHASE1":3704,"PHASE1":3706,"PHASE2":3708,"PHASE3":3710,"PHASE4":3712,"NA":3714},{"trials":3705,"activeCount":98},[],{"trials":3707,"activeCount":98},[],{"trials":3709,"activeCount":98},[],{"trials":3711,"activeCount":98},[],{"trials":3713,"activeCount":98},[],{"trials":3715,"activeCount":98},[3716],{"nctId":3717,"briefTitle":3718,"status":201,"phases":3719,"primaryCompletion":3720,"completion":3720,"start":3721,"enrollment":2791,"conditions":3722,"interventions":3724},"NCT03792451","Nutrition Status of Adults Treated With Pegvaliase",[],"2020-12-31","2019-01-17",[3723],"Phenylketonurias",[3702],{"intervention":3726,"totalTrials":144,"cells":3727},"Second Line ITP agents",{"EARLY_PHASE1":3728,"PHASE1":3730,"PHASE2":3732,"PHASE3":3734,"PHASE4":3736,"NA":3738},{"trials":3729,"activeCount":98},[],{"trials":3731,"activeCount":98},[],{"trials":3733,"activeCount":98},[],{"trials":3735,"activeCount":98},[],{"trials":3737,"activeCount":98},[],{"trials":3739,"activeCount":98},[3740],{"nctId":3741,"briefTitle":3742,"status":201,"phases":3743,"primaryCompletion":891,"completion":891,"start":1300,"enrollment":190,"conditions":3744,"interventions":3746},"NCT01971684","ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP",[],[3745],"Immune Thrombocytopenia",[3726],{"intervention":3748,"totalTrials":144,"cells":3749},"Hepatitis B vaccine",{"EARLY_PHASE1":3750,"PHASE1":3752,"PHASE2":3754,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3751,"activeCount":98},[],{"trials":3753,"activeCount":98},[],{"trials":3755,"activeCount":98},[],{"trials":3757,"activeCount":98},[],{"trials":3759,"activeCount":98},[],{"trials":3761,"activeCount":98},[3762],{"nctId":3763,"briefTitle":3764,"status":201,"phases":3765,"primaryCompletion":3766,"completion":3766,"start":3767,"enrollment":3768,"conditions":3769,"interventions":3771},"NCT03246230","Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity",[90],"2022-08-29","2017-09-06",911,[3770],"Newborn Vaccine Immunogenicity",[3748,3772],"Bacillus Calmette-Guérin",{"intervention":3772,"totalTrials":144,"cells":3774},{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3781,"PHASE4":3783,"NA":3785},{"trials":3776,"activeCount":98},[],{"trials":3778,"activeCount":98},[],{"trials":3780,"activeCount":98},[],{"trials":3782,"activeCount":98},[],{"trials":3784,"activeCount":98},[],{"trials":3786,"activeCount":98},[3787],{"nctId":3763,"briefTitle":3764,"status":201,"phases":3788,"primaryCompletion":3766,"completion":3766,"start":3767,"enrollment":3768,"conditions":3789,"interventions":3790},[90],[3770],[3748,3772],{"intervention":3792,"totalTrials":144,"cells":3793},"Supplemental Vitamin D",{"EARLY_PHASE1":3794,"PHASE1":3796,"PHASE2":3798,"PHASE3":3800,"PHASE4":3802,"NA":3804},{"trials":3795,"activeCount":98},[],{"trials":3797,"activeCount":98},[],{"trials":3799,"activeCount":98},[],{"trials":3801,"activeCount":98},[],{"trials":3803,"activeCount":98},[],{"trials":3805,"activeCount":98},[3806],{"nctId":3807,"briefTitle":3808,"status":201,"phases":3809,"primaryCompletion":2899,"completion":2899,"start":1648,"enrollment":11,"conditions":3810,"interventions":3812},"NCT01126671","Vitamin D Supplementation in Healthy Adolescents",[90],[3811],"Vitamin D Supplementation",[3792],{"intervention":1283,"totalTrials":144,"cells":3814},{"EARLY_PHASE1":3815,"PHASE1":3817,"PHASE2":3819,"PHASE3":3821,"PHASE4":3823,"NA":3825},{"trials":3816,"activeCount":98},[],{"trials":3818,"activeCount":98},[],{"trials":3820,"activeCount":98},[],{"trials":3822,"activeCount":98},[],{"trials":3824,"activeCount":98},[],{"trials":3826,"activeCount":98},[3827],{"nctId":1271,"briefTitle":1272,"status":201,"phases":3828,"primaryCompletion":1274,"completion":462,"start":1275,"enrollment":463,"conditions":3829,"interventions":3830},[90],[1277,1278,1279,1280,35,1281],[70,1283,1284,1285],{"intervention":3832,"totalTrials":144,"cells":3833},"euglycemic insulin clamp",{"EARLY_PHASE1":3834,"PHASE1":3836,"PHASE2":3838,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3835,"activeCount":98},[],{"trials":3837,"activeCount":98},[],{"trials":3839,"activeCount":98},[],{"trials":3841,"activeCount":98},[],{"trials":3843,"activeCount":98},[],{"trials":3845,"activeCount":98},[3846],{"nctId":3847,"briefTitle":3848,"status":201,"phases":3849,"primaryCompletion":3850,"completion":3850,"start":2766,"enrollment":1252,"conditions":3851,"interventions":3853},"NCT02772783","Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus",[90],"2018-05",[3852],"Diabetes Mellitus, Type 1",[3832,3854],"primed-variable insulin",{"intervention":3854,"totalTrials":144,"cells":3856},{"EARLY_PHASE1":3857,"PHASE1":3859,"PHASE2":3861,"PHASE3":3863,"PHASE4":3865,"NA":3867},{"trials":3858,"activeCount":98},[],{"trials":3860,"activeCount":98},[],{"trials":3862,"activeCount":98},[],{"trials":3864,"activeCount":98},[],{"trials":3866,"activeCount":98},[],{"trials":3868,"activeCount":98},[3869],{"nctId":3847,"briefTitle":3848,"status":201,"phases":3870,"primaryCompletion":3850,"completion":3850,"start":2766,"enrollment":1252,"conditions":3871,"interventions":3872},[90],[3852],[3832,3854],{"intervention":3874,"totalTrials":144,"cells":3875},"(Optional) Saliva Collection",{"EARLY_PHASE1":3876,"PHASE1":3878,"PHASE2":3880,"PHASE3":3882,"PHASE4":3884,"NA":3886},{"trials":3877,"activeCount":98},[],{"trials":3879,"activeCount":98},[],{"trials":3881,"activeCount":98},[],{"trials":3883,"activeCount":98},[],{"trials":3885,"activeCount":98},[],{"trials":3887,"activeCount":98},[3888],{"nctId":3889,"briefTitle":3890,"status":2128,"phases":3891,"primaryCompletion":3892,"completion":3892,"start":3893,"enrollment":128,"conditions":3894,"interventions":3895},"NCT04706364","Investigation of Brain Plasticity in Autism Spectrum Disorders",[],"2022-05","2019-06-10",[26],[3874],{"intervention":3897,"totalTrials":144,"cells":3898},"Local Anesthetics,",{"EARLY_PHASE1":3899,"PHASE1":3901,"PHASE2":3903,"PHASE3":3905,"PHASE4":3907,"NA":3909},{"trials":3900,"activeCount":98},[],{"trials":3902,"activeCount":98},[],{"trials":3904,"activeCount":98},[],{"trials":3906,"activeCount":98},[],{"trials":3908,"activeCount":98},[],{"trials":3910,"activeCount":98},[3911],{"nctId":3912,"briefTitle":3913,"status":1596,"phases":3914,"primaryCompletion":3915,"completion":3915,"start":3916,"enrollment":98,"conditions":3917,"interventions":3919},"NCT03342079","Effectiveness of Nitrous Oxide 50% for Reducing Pain and Distress Associated with Needle-stick in Children",[90],"2014-12","2014-03",[3918],"Local Anesthetic Efficacy",[3897,3920],"Placebos",{"intervention":3920,"totalTrials":144,"cells":3922},{"EARLY_PHASE1":3923,"PHASE1":3925,"PHASE2":3927,"PHASE3":3929,"PHASE4":3931,"NA":3933},{"trials":3924,"activeCount":98},[],{"trials":3926,"activeCount":98},[],{"trials":3928,"activeCount":98},[],{"trials":3930,"activeCount":98},[],{"trials":3932,"activeCount":98},[],{"trials":3934,"activeCount":98},[3935],{"nctId":3912,"briefTitle":3913,"status":1596,"phases":3936,"primaryCompletion":3915,"completion":3915,"start":3916,"enrollment":98,"conditions":3937,"interventions":3938},[90],[3918],[3897,3920],{"intervention":3940,"totalTrials":144,"cells":3941},"Brand Name Levothyroxine",{"EARLY_PHASE1":3942,"PHASE1":3944,"PHASE2":3946,"PHASE3":3948,"PHASE4":3950,"NA":3952},{"trials":3943,"activeCount":98},[],{"trials":3945,"activeCount":98},[],{"trials":3947,"activeCount":98},[],{"trials":3949,"activeCount":98},[],{"trials":3951,"activeCount":98},[],{"trials":3953,"activeCount":98},[3954],{"nctId":3955,"briefTitle":3956,"status":201,"phases":3957,"primaryCompletion":3958,"completion":3959,"start":3610,"enrollment":3497,"conditions":3960,"interventions":3963},"NCT00403390","Generic vs. Name-Brand Levothyroxine",[90],"2009-12","2010-03",[3961,3962],"Congenital Hypothyroidism","Hypothyroidism",[3940,3964],"Generic formulation of Levothyroxine",{"intervention":3964,"totalTrials":144,"cells":3966},{"EARLY_PHASE1":3967,"PHASE1":3969,"PHASE2":3971,"PHASE3":3973,"PHASE4":3975,"NA":3977},{"trials":3968,"activeCount":98},[],{"trials":3970,"activeCount":98},[],{"trials":3972,"activeCount":98},[],{"trials":3974,"activeCount":98},[],{"trials":3976,"activeCount":98},[],{"trials":3978,"activeCount":98},[3979],{"nctId":3955,"briefTitle":3956,"status":201,"phases":3980,"primaryCompletion":3958,"completion":3959,"start":3610,"enrollment":3497,"conditions":3981,"interventions":3982},[90],[3961,3962],[3940,3964],{"intervention":3984,"totalTrials":144,"cells":3985},"Calcitonin nasal spray",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":3992,"PHASE4":3994,"NA":3996},{"trials":3987,"activeCount":98},[],{"trials":3989,"activeCount":98},[],{"trials":3991,"activeCount":98},[],{"trials":3993,"activeCount":98},[],{"trials":3995,"activeCount":98},[],{"trials":3997,"activeCount":98},[3998],{"nctId":3999,"briefTitle":4000,"status":201,"phases":4001,"completion":719,"start":4002,"enrollment":114,"conditions":4003,"interventions":4005},"NCT00114803","Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease",[90],"2004-01",[2135,4004],"Crohn's Disease",[3984],{"intervention":4007,"totalTrials":144,"cells":4008},"Mebendazole Pill",{"EARLY_PHASE1":4009,"PHASE1":4011,"PHASE2":4013,"PHASE3":4015,"PHASE4":4017,"NA":4019},{"trials":4010,"activeCount":98},[],{"trials":4012,"activeCount":98},[],{"trials":4014,"activeCount":98},[],{"trials":4016,"activeCount":98},[],{"trials":4018,"activeCount":98},[],{"trials":4020,"activeCount":98},[4021],{"nctId":4022,"briefTitle":4023,"status":1596,"phases":4024,"primaryCompletion":4025,"completion":4025,"start":4026,"enrollment":98,"conditions":4027,"interventions":4035},"NCT05073562","Nutrition Intervention to Address Anemia Among Adolescent Girls in Liberia",[90],"2021-12","2021-10",[4028,4029,4030,4031,4032,4033,4034],"Nutritional Anemia","Nutritional Deficiency","Iron Deficiency Anemia Treatment","Folic Acid Deficiency Anemia, Dietary","Adolescent Development","Knowledge, Attitudes, Practice","Food Habits",[4007],{"intervention":4037,"totalTrials":144,"cells":4038},"piperacillin-tazobactam",{"EARLY_PHASE1":4039,"PHASE1":4041,"PHASE2":4043,"PHASE3":4045,"PHASE4":4047,"NA":4049},{"trials":4040,"activeCount":98},[],{"trials":4042,"activeCount":98},[],{"trials":4044,"activeCount":98},[],{"trials":4046,"activeCount":98},[],{"trials":4048,"activeCount":98},[],{"trials":4050,"activeCount":98},[4051],{"nctId":4052,"briefTitle":4053,"status":565,"phases":4054,"primaryCompletion":4055,"completion":4056,"start":4057,"enrollment":2016,"conditions":4058,"interventions":4059},"NCT03922451","Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support",[],"2020-04-01","2022-02-28","2019-08-27",[1309],[4037,4060],"Cefazolin",{"intervention":4060,"totalTrials":144,"cells":4062},{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4067,"PHASE3":4069,"PHASE4":4071,"NA":4073},{"trials":4064,"activeCount":98},[],{"trials":4066,"activeCount":98},[],{"trials":4068,"activeCount":98},[],{"trials":4070,"activeCount":98},[],{"trials":4072,"activeCount":98},[],{"trials":4074,"activeCount":98},[4075],{"nctId":4052,"briefTitle":4053,"status":565,"phases":4076,"primaryCompletion":4055,"completion":4056,"start":4057,"enrollment":2016,"conditions":4077,"interventions":4078},[],[1309],[4037,4060],{"intervention":4080,"totalTrials":144,"cells":4081},"Hyoscyamine",{"EARLY_PHASE1":4082,"PHASE1":4084,"PHASE2":4086,"PHASE3":4088,"PHASE4":4090,"NA":4092},{"trials":4083,"activeCount":98},[],{"trials":4085,"activeCount":98},[],{"trials":4087,"activeCount":98},[],{"trials":4089,"activeCount":98},[],{"trials":4091,"activeCount":98},[],{"trials":4093,"activeCount":98},[4094],{"nctId":4095,"briefTitle":4096,"status":201,"phases":4097,"primaryCompletion":1599,"completion":1599,"start":1250,"enrollment":4098,"conditions":4099,"interventions":4104},"NCT02389998","Efficacy of Open Label Placebo in Children With FGIDs",[90],31,[4100,4101,4102,4103],"Functional Abdominal Pain","Functional Dyspepsia","Irritable Bowel Syndrome","Functional Gastrointestinal Disorders",[4080],{"intervention":4106,"totalTrials":144,"cells":4107},"Zinc Sulfate",{"EARLY_PHASE1":4108,"PHASE1":4110,"PHASE2":4112,"PHASE3":4114,"PHASE4":4116,"NA":4118},{"trials":4109,"activeCount":98},[],{"trials":4111,"activeCount":98},[],{"trials":4113,"activeCount":98},[],{"trials":4115,"activeCount":98},[],{"trials":4117,"activeCount":98},[],{"trials":4119,"activeCount":98},[4120],{"nctId":4121,"briefTitle":4122,"status":201,"phases":4123,"primaryCompletion":4124,"completion":4125,"start":1440,"enrollment":4126,"conditions":4127,"interventions":4130},"NCT01198587","Oral Zinc for the Treatment of Acute Diarrhea in US Children",[90],"2014-06","2015-06",71,[4128,4129],"Diarrhea","Gastroenteritis",[4106],{"intervention":4132,"totalTrials":144,"cells":4133},"ESES treated with clobazam",{"EARLY_PHASE1":4134,"PHASE1":4136,"PHASE2":4138,"PHASE3":4140,"PHASE4":4142,"NA":4144},{"trials":4135,"activeCount":98},[],{"trials":4137,"activeCount":98},[],{"trials":4139,"activeCount":98},[],{"trials":4141,"activeCount":98},[],{"trials":4143,"activeCount":98},[],{"trials":4145,"activeCount":98},[4146],{"nctId":4147,"briefTitle":4148,"status":201,"phases":4149,"primaryCompletion":4150,"completion":4150,"start":550,"enrollment":4151,"conditions":4152,"interventions":4154},"NCT02127918","Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment",[],"2015-07",17,[4153],"Electrical Status Epilepticus in Sleep",[4132],{"intervention":4156,"totalTrials":144,"cells":4157},"Antacids",{"EARLY_PHASE1":4158,"PHASE1":4160,"PHASE2":4162,"PHASE3":4164,"PHASE4":4166,"NA":4168},{"trials":4159,"activeCount":98},[],{"trials":4161,"activeCount":98},[],{"trials":4163,"activeCount":98},[],{"trials":4165,"activeCount":98},[],{"trials":4167,"activeCount":98},[],{"trials":4169,"activeCount":98},[4170],{"nctId":4171,"briefTitle":4172,"status":2128,"phases":4173,"primaryCompletion":4174,"completion":4174,"start":1693,"enrollment":2132,"conditions":4175,"interventions":4177},"NCT03619408","Management of Esophagitis Following Repair of Esophageal Atresia",[],"2025-07",[2416,4176],"Esophagitis",[4156],{"intervention":4179,"totalTrials":144,"cells":4180},"Teduglutide",{"EARLY_PHASE1":4181,"PHASE1":4183,"PHASE2":4185,"PHASE3":4187,"PHASE4":4189,"NA":4191},{"trials":4182,"activeCount":98},[],{"trials":4184,"activeCount":98},[],{"trials":4186,"activeCount":98},[],{"trials":4188,"activeCount":98},[],{"trials":4190,"activeCount":98},[],{"trials":4192,"activeCount":98},[4193],{"nctId":4194,"briefTitle":4195,"status":201,"phases":4196,"primaryCompletion":4197,"completion":4197,"start":4198,"enrollment":4199,"conditions":4200,"interventions":4201},"NCT04832087","Pediatric Teduglutide Registry",[],"2023-08-31","2021-05-18",142,[2472],[4179],{"intervention":3578,"totalTrials":144,"cells":4203},{"EARLY_PHASE1":4204,"PHASE1":4206,"PHASE2":4208,"PHASE3":4210,"PHASE4":4212,"NA":4214},{"trials":4205,"activeCount":98},[],{"trials":4207,"activeCount":98},[],{"trials":4209,"activeCount":98},[],{"trials":4211,"activeCount":98},[],{"trials":4213,"activeCount":98},[],{"trials":4215,"activeCount":98},[4216],{"nctId":3571,"briefTitle":3572,"status":201,"phases":4217,"primaryCompletion":3574,"completion":3574,"start":3211,"enrollment":3575,"conditions":4218,"interventions":4219},[90],[35,1281],[3578,1603],{"intervention":4221,"totalTrials":144,"cells":4222},"vancomycin hydrocloride",{"EARLY_PHASE1":4223,"PHASE1":4225,"PHASE2":4227,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4224,"activeCount":98},[],{"trials":4226,"activeCount":98},[],{"trials":4228,"activeCount":98},[],{"trials":4230,"activeCount":98},[],{"trials":4232,"activeCount":98},[],{"trials":4234,"activeCount":98},[4235],{"nctId":4236,"briefTitle":4237,"status":565,"phases":4238,"primaryCompletion":4239,"completion":2459,"start":1879,"enrollment":4240,"conditions":4241,"interventions":4242},"NCT01290237","Use of a Loading Dose of Vancomycin in Pediatric Dosing",[90],"2012-02",59,[209],[4221],{"intervention":4244,"totalTrials":144,"cells":4245},"Gardasil vaccine",{"EARLY_PHASE1":4246,"PHASE1":4248,"PHASE2":4250,"PHASE3":4252,"PHASE4":4254,"NA":4256},{"trials":4247,"activeCount":98},[],{"trials":4249,"activeCount":98},[],{"trials":4251,"activeCount":98},[],{"trials":4253,"activeCount":98},[],{"trials":4255,"activeCount":98},[],{"trials":4257,"activeCount":98},[4258],{"nctId":4259,"briefTitle":4260,"status":201,"phases":4261,"primaryCompletion":3342,"completion":1301,"start":4262,"enrollment":650,"conditions":4263,"interventions":4265},"NCT00727636","Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy",[90],"2008-07",[4264],"Inflammatory Bowel Disease",[4244]]